A general term for various neoplastic diseases of the lymphoid tissue.
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.
A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.
B-cell lymphoid tumors that occur in association with AIDS. Patients often present with an advanced stage of disease and highly malignant subtypes including BURKITT LYMPHOMA; IMMUNOBLASTIC LARGE-CELL LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; and DIFFUSE, LARGE B-CELL, LYMPHOMA. The tumors are often disseminated in unusual extranodal sites and chromosomal abnormalities are frequently present. It is likely that polyclonal B-cell lymphoproliferation in AIDS is a complex result of EBV infection, HIV antigenic stimulation, and T-cell-dependent HIV activation.
A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called "hallmark" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
Malignant lymphoma characterized by the presence of immunoblasts with uniformly round-to-oval nuclei, one or more prominent nucleoli, and abundant cytoplasm. This class may be subdivided into plasmacytoid and clear-cell types based on cytoplasmic characteristics. A third category, pleomorphous, may be analogous to some of the peripheral T-cell lymphomas (LYMPHOMA, T-CELL, PERIPHERAL) recorded in both the United States and Japan.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Antibodies obtained from a single clone of cells grown in mice or rats.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome.
An extranodal neoplasm, usually possessing an NK-cell phenotype and associated with EPSTEIN-BARR VIRUS. These lymphomas exhibit a broad morphologic spectrum, frequent necrosis, angioinvasion, and most commonly present in the midfacial region, but also in other extranodal sites.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
A specific pair of GROUP D CHROMOSOMES of the human chromosome classification.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. They are found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
A specific pair of GROUP E CHROMOSOMES of the human chromosome classification.
The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development.
A DNA-binding protein that represses GENETIC TRANSCRIPTION of target genes by recruiting HISTONE DEACETYLASES. Aberrant Blc-6 expression is associated with certain types of human B-CELL LYMPHOMA.
Tumors or cancer of the THYMUS GLAND.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
Antibodies produced by a single clone of cells.
Large cells, usually multinucleate, whose presence is a common histologic characteristic of classical HODGKIN DISEASE.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Tumors or cancer of the EYE.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
A group of disorders having a benign course but exhibiting clinical and histological features suggestive of malignant lymphoma. Pseudolymphoma is characterized by a benign infiltration of lymphoid cells or histiocytes which microscopically resembles a malignant lymphoma. (From Dorland, 28th ed & Stedman, 26th ed)
Tumors or cancer of the NOSE.
Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).
A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.
Therapeutic act or process that initiates a response to a complete or partial remission level.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Tumors or cancer of the SKIN.
Transplantation of an individual's own tissue from one site to another site.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
The activated center of a lymphoid follicle in secondary lymphoid tissue where B-LYMPHOCYTES are stimulated by antigens and helper T cells (T-LYMPHOCYTES, HELPER-INDUCER) are stimulated to generate memory cells.
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
DNA present in neoplastic tissue.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.
Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.
A cell line derived from cultured tumor cells.
Tumors or cancer of the MEDIASTINUM.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Genes encoding the different subunits of the IMMUNOGLOBULINS, for example the IMMUNOGLOBULIN LIGHT CHAIN GENES and the IMMUNOGLOBULIN HEAVY CHAIN GENES. The heavy and light immunoglobulin genes are present as gene segments in the germline cells. The completed genes are created when the segments are shuffled and assembled (B-LYMPHOCYTE GENE REARRANGEMENT) during B-LYMPHOCYTE maturation. The gene segments of the human light and heavy chain germline genes are symbolized V (variable), J (joining) and C (constant). The heavy chain germline genes have an additional segment D (diversity).
Family of retrovirus-associated DNA sequences (myc) originally isolated from an avian myelocytomatosis virus. The proto-oncogene myc (c-myc) codes for a nuclear protein which is involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Truncation of the first exon, which appears to regulate c-myc expression, is crucial for tumorigenicity. The human c-myc gene is located at 8q24 on the long arm of chromosome 8.
Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.
Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).
Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.
A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.
The B-cell leukemia/lymphoma-2 genes, responsible for blocking apoptosis in normal cells, and associated with follicular lymphoma when overexpressed. Overexpression results from the t(14;18) translocation. The human c-bcl-2 gene is located at 18q24 on the long arm of chromosome 18.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
An experimental lymphocytic leukemia of mice.
A primary peripheral T-cell lymphoma in the gastrointestinal tract, most often in the jejunum, associated with a history of CELIAC DISEASE or other gastrointestinal diseases.
Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.
Ordered rearrangement of B-lymphocyte variable gene regions coding for the IMMUNOGLOBULIN CHAINS, thereby contributing to antibody diversity. It occurs during the differentiation of the IMMATURE B-LYMPHOCYTES.
Two or more distinct types of malignant lymphoid tumors occurring within a single organ or tissue at the same time. It may contain different types of non-Hodgkin lymphoma cells or both Hodgkin and non-Hodgkin lymphoma cells.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tumors or cancer of the INTESTINES.
The return of a sign, symptom, or disease after a remission.
Ordered rearrangement of B-lymphocyte variable gene regions of the IMMUNOGLOBULIN HEAVY CHAINS, thereby contributing to antibody diversity. It occurs during the first stage of differentiation of the IMMATURE B-LYMPHOCYTES.
An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Enzyme that is a major constituent of kidney brush-border membranes and is also present to a lesser degree in the brain and other tissues. It preferentially catalyzes cleavage at the amino group of hydrophobic residues of the B-chain of insulin as well as opioid peptides and other biologically active peptides. The enzyme is inhibited primarily by EDTA, phosphoramidon, and thiorphan and is reactivated by zinc. Neprilysin is identical to common acute lymphoblastic leukemia antigen (CALLA Antigen), an important marker in the diagnosis of human acute lymphocytic leukemia. There is no relationship with CALLA PLANT.
A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.
A therapeutic approach, involving chemotherapy, radiation therapy, or surgery, after initial regimens have failed to lead to improvement in a patient's condition. Salvage therapy is most often used for neoplastic diseases.
Neoplasms of the bony orbit and contents except the eyeball.
Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)
An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Genes and gene segments encoding the IMMUNOGLOBULIN HEAVY CHAINS. Gene segments of the heavy chain genes are symbolized V (variable), D (diversity), J (joining), and C (constant).
IMMUNOGLOBULINS on the surface of B-LYMPHOCYTES. Their MESSENGER RNA contains an EXON with a membrane spanning sequence, producing immunoglobulins in the form of type I transmembrane proteins as opposed to secreted immunoglobulins (ANTIBODIES) which do not contain the membrane spanning segment.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
A species in the genus RHADINOVIRUS, subfamily GAMMAHERPESVIRINAE, isolated from patients with AIDS-related and "classical" Kaposi sarcoma.
Tumors or cancer of the STOMACH.
Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Cellular DNA-binding proteins encoded by the c-myc genes. They are normally involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Elevated and deregulated (constitutive) expression of c-myc proteins can cause tumorigenesis.
Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS.
A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
A lectin and cell adhesion molecule found in B-LYMPHOCYTES. It interacts with SIALIC ACIDS and mediates signaling from B-CELL ANTIGEN RECEPTORS.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
A class of cellular receptors that have an intrinsic PROTEIN-TYROSINE KINASE activity.
A component of the B-cell antigen receptor that is involved in B-cell antigen receptor heavy chain transport to the PLASMA MEMBRANE. It is expressed almost exclusively in B-LYMPHOCYTES and serves as a useful marker for B-cell NEOPLASMS.
Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.
Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Unstable isotopes of gallium that decay or disintegrate emitting radiation. Ga atoms with atomic weights 63-68, 70 and 72-76 are radioactive gallium isotopes.
Nuclear antigens encoded by VIRAL GENES found in HUMAN HERPESVIRUS 4. At least six nuclear antigens have been identified.
A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.
Established cell cultures that have the potential to propagate indefinitely.
Elements of limited time intervals, contributing to particular results or situations.
Mapping of the KARYOTYPE of a cell.
An imaging technique using compounds labelled with short-lived positron-emitting radionuclides (such as carbon-11, nitrogen-13, oxygen-15 and fluorine-18) to measure cell metabolism. It has been useful in study of soft tissues such as CANCER; CARDIOVASCULAR SYSTEM; and brain. SINGLE-PHOTON EMISSION-COMPUTED TOMOGRAPHY is closely related to positron emission tomography, but uses isotopes with longer half-lives and resolution is lower.
A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.
Ordered rearrangement of T-cell variable gene regions coding for the gamma-chain of antigen receptors.
Macrophages found in the TISSUES, as opposed to those found in the blood (MONOCYTES) or serous cavities (SEROUS MEMBRANE).
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Specialized tissues that are components of the lymphatic system. They provide fixed locations within the body where a variety of LYMPHOCYTES can form, mature and multiply. The lymphoid tissues are connected by a network of LYMPHATIC VESSELS.
Ordered rearrangement of T-cell variable gene regions coding for the antigen receptors.
A form of malignant cancer which occurs within the eyeball.
Unstable isotopes of yttrium that decay or disintegrate emitting radiation. Y atoms with atomic weights 82-88 and 90-96 are radioactive yttrium isotopes.
A method (first developed by E.M. Southern) for detection of DNA that has been electrophoretically separated and immobilized by blotting on nitrocellulose or other type of paper or nylon membrane followed by hybridization with labeled NUCLEIC ACID PROBES.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
The compound is given by intravenous injection to do POSITRON-EMISSION TOMOGRAPHY for the assessment of cerebral and myocardial glucose metabolism in various physiological or pathological states including stroke and myocardial ischemia. It is also employed for the detection of malignant tumors including those of the brain, liver, and thyroid gland. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1162)
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification.
A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Experimental transplantation of neoplasms in laboratory animals for research purposes.
Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.
A malignant disease of the T-LYMPHOCYTES in the bone marrow, thymus, and/or blood.
The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.
An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.
Infections produced by oncogenic viruses. The infections caused by DNA viruses are less numerous but more diverse than those caused by the RNA oncogenic viruses.
A transcription factor that is essential for CELL DIFFERENTIATION of B-LYMPHOCYTES. It functions both as a transcriptional activator and repressor to mediate B-cell commitment.
General term for inflammation of adipose tissue, usually of the skin, characterized by reddened subcutaneous nodules.
Tumors or cancer of the PALATINE TONSIL.
Tumors or cancer of the CONJUNCTIVA.
Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type.
A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time.
Virus diseases caused by the HERPESVIRIDAE.
A family of transcription factors that share an N-terminal HELIX-TURN-HELIX MOTIF and bind INTERFERON-inducible promoters to control GENE expression. IRF proteins bind specific DNA sequences such as interferon-stimulated response elements, interferon regulatory elements, and the interferon consensus sequence.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
Removal and examination of tissue obtained through a transdermal needle inserted into the specific region, organ, or tissue being analyzed.
RNA present in neoplastic tissue.
Proteins associated with the inner surface of the lipid bilayer of the viral envelope. These proteins have been implicated in control of viral transcription and may possibly serve as the "glue" that binds the nucleocapsid to the appropriate membrane site during viral budding from the host cell.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule.
Leukemia induced experimentally in animals by exposure to leukemogenic agents, such as VIRUSES; RADIATION; or by TRANSPLANTATION of leukemic tissues.
That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions.
Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Inorganic or organic compounds that contain the basic structure RB(OH)2.
The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.
The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin.
Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.)
The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
Anaplastic lymphoma of the skin which develops as a primary neoplasm expressing the CD30 ANTIGEN. It is characterized by solitary nodules or ulcerated tumors.
A technique that localizes specific nucleic acid sequences within intact chromosomes, eukaryotic cells, or bacterial cells through the use of specific nucleic acid-labeled probes.
Diseases of the domestic dog (Canis familiaris). This term does not include diseases of wild dogs, WOLVES; FOXES; and other Canidae for which the heading CARNIVORA is used.
A spiral bacterium active as a human gastric pathogen. It is a gram-negative, urease-positive, curved or slightly spiral organism initially isolated in 1982 from patients with lesions of gastritis or peptic ulcers in Western Australia. Helicobacter pylori was originally classified in the genus CAMPYLOBACTER, but RNA sequencing, cellular fatty acid profiles, growth patterns, and other taxonomic characteristics indicate that the micro-organism should be included in the genus HELICOBACTER. It has been officially transferred to Helicobacter gen. nov. (see Int J Syst Bacteriol 1989 Oct;39(4):297-405).
A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Protein encoded by the bcl-1 gene which plays a critical role in regulating the cell cycle. Overexpression of cyclin D1 is the result of bcl-1 rearrangement, a t(11;14) translocation, and is implicated in various neoplasms.
The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.
Tumors or cancer of the PAROTID GLAND.

Carcinogenicity of triethanolamine in mice and its mutagenicity after reaction with sodium nitrite in bacteria. (1/6021)

Mice fed a diet containing 0.3 or 0.03% triethanolamine developed malignant tumors. Females showed a high incidence of tumors in lymphoid tissues, while this type was absent in males. Tumors in other tissues were produced at a considerable rate in both sexes, but no hepatoma was found. Triethanolamine was not mutagenic to Bacillus subtilis by itself, but it became mutagenic after reacting with sodium nitrite under acidic conditions or when the mixture was heated. Although N-nitrosodiethanolamine, a known carcinogen and mutagen, was detected in the reaction mixture by thin-layer chromatography, it may not be the main mutagenic product, because the product was a stable and direct mutagen and its mutagenic activity was destroyed by liver enzymes, unlike N-nitrosodiethanolamine. The lethal and mutagenic DNA damages produced by this unidentified product were susceptible to some extent to the repair functions of the bacteria.  (+info)

Immune responses to all ErbB family receptors detectable in serum of cancer patients. (2/6021)

Employing NIH3T3 transfectants with individual human ErbB receptor coding sequences as recombinant antigen sources, we detected by immunoblot analysis specific immunoreactivity against all four ErbB receptors among 13 of 41 sera obtained from patients with different types of epithelial malignancies. Overall, serum positivity was most frequently directed against ErbB2 followed by EGFR, ErbB3 and ErbB4. Specificity patterns comprised tumor patients with unique serum reactivity against ErbB2 or ErbB4. Moreover, approximately half of the positive sera exhibited concomitant reactivity with multiple ErbB receptors including EGFR and ErbB2, EGFR and ErbB4, ErbB2 and ErbB3 or EGFR, ErbB2 and ErbB3. Serum reactivity was confirmed for the respective ErbB receptors expressed by human tumor cells and corroborated on receptor-specific immunoprecipitates. Positive sera contained ErbB-specific antibodies of the IgG isotype. Representative immunohistochemical analysis of tumor tissues suggested overexpression of ErbB receptors for which serum antibodies were detectable in five of six patients. These findings implicate multiple ErbB receptors including ErbB3 and ErbB4 in addition to EGFR and ErbB2 in primary human cancer. Heterogeneity of natural ErbB-specific responses in cancer patients warrants their evaluation in light of immunotherapeutic approaches targeting these receptors.  (+info)

ATF-2-binding regulatory element is responsible for the Ly49A expression in murine T lymphoid line, EL-4. (3/6021)

To understand the mechanism of Ly49A-expression and its significance in T-cell differentiation, we analyzed the 5'-flanking region of the Ly49A gene in a search for the Ly49A-regulatory element. Since very few known regulatory elements have been found in this region, presumably a novel regulatory sequence(s) could exist. Accordingly, we defined the 13-bp regulatory element, 5'-ATGACGAGGAGGA-3', restricted to Ly49A-expression in EL-4 cells in comparison with two other representative cell lines tested. This element, designated as EL13, proved to be previously undiscovered by homology search and is highly homologous with several virus DNAs. Using EL13 as a probe we have cloned a cDNA encoding a binding protein to EL13. Its deduced nucleotide sequence revealed that EL13-binding protein is almost identical with rat ATF-2. Although ATF-2 is known to bind to cyclic AMP responsive element (CRE), EL13 shares five out of eight nucleotides with this consensus sequence. Our results suggested that ATF-2 may play an important role via binding to EL13 for the expression of Ly49A. These data will provide useful information for understanding T-cell and NK-cell differentiation in murine immune system.  (+info)

Incidence and occupational pattern of leukaemias, lymphomas, and testicular tumours in western Ireland over an 11 year period. (4/6021)

STUDY OBJECTIVE: To determine incidence of the following malignancies, testicular tumours, all leukaemias and all lymphomas in the West of Ireland in an 11 year period. Secondly, to examine the relation between disease patterns and available occupational data in male subjects of working age. DESIGN: A census survey of all cases occurring in the three counties in the Western Health Board (WHB) area, Galway, Mayo and Roscommon, for the 11 year period 1980 to 1990 inclusive. Average annual age standardised incidence rates for the period were calculated using the 1986 census data. Rates for the area are compared with rates from the southern region of Ireland, which had a tumour registry. Trends over the time period are evaluated. All male subjects for whom occupational data were available were categorised using the Irish socioeconomic group classification and incidence rates by occupation were compared using the standardised incidence ratio method. In one of the counties, Galway, a detailed occupational history of selected cases and an age matched control group was also elicited through patients' general practitioners. SETTING: All available case records in the West of Ireland. RESULTS: There are no national incidence records for the period. Compared with data from the Southern Tumour Registry, the number of cases of women with myeloid leukaemias was significantly lower. Male leukaemia rates were significantly lower as a group (SIR 84 (95% CI 74, 95) but not when considered as individual categories. Regression analysis revealed an increasing trend in the number of new cases of non-Hodgkin's lymphoma among both men (r = 0.47, p = 0.02) and women (r = 0.90, p = 0.0001) and of chronic lymphocytic leukaemia in men (r = 0.77, p = 0.005) and women (r = 0.68 p = 0.02) in the WHB region over the last decade. Four hundred and fifty six male cases over the age of 15 years were identified and adequate occupational information was available for 74% of these. Standardised incidence ratios of testicular tumours 100, 938) and agriworkers other than farmers (SIR 377, 95% CI 103, 967). There were also significantly increased incidence ratios for both non-Hodgkin's lymphoma (SIR 169, 95% CI 124, 266) and three categories of leukaemias among farmers. Hodgkin's disease and acute myeloid leukaemias were significantly increased among semi-skilled people. Interview data with 90 cases and 54 controls of both sexes revealed that among farmers, cases (n = 31) were significantly less likely than controls (n = 20) to use tractor mounted spraying techniques (OR = 0.19 (95% CI 0.04, 0.80)) and less likely to wear protective masks (OR 0.22 (95% CI 0.05, 0.84)). CONCLUSIONS: Trends of increase in non-Hodgkin's lymphoma and some leukaemias are consistent with studies elsewhere. The study provides further evidence of the relation between agricultural work and certain lymphoproliferative cancers. The possible carcinogenic role of chemicals used in agricultural industries must be considered as an explanation.  (+info)

A case of primary lymphoma of the liver. (5/6021)

A case of primary malignant lymphoma of the liver is described. Presenting with epistaxis, he died in hepatic encephalopathy with an intractable bleeding post-bulbar duodenal ulcer.  (+info)

Ovine MHC class II DRB1 alleles associated with resistance or susceptibility to development of bovine leukemia virus-induced ovine lymphoma. (6/6021)

For the further characterization of bovine leukemia virus (BLV)-induced leukemogenesis, we investigated the association between polymorphism of ovine leukocyte antigen (OLA)-DRB1 gene and tumor development after infection of sheep with BLV. We infected 28 sheep with BLV and cloned exon 2 of the OLA-DRB1 gene from asymptomatic animals and from animals with lymphoma Sequence analysis revealed that, among 12 healthy sheep without any evidence of tumor, ten (83.3%) carried DRB1 alleles encoding Arg-Lys (RK) at positions beta70/71 as compared with only 6 (37.5%) of the 16 sheep with lymphoma, which suggested that alleles encoding the RK motif might protect against development of tumors after infection by BLV. By contrast, alleles encoding Ser-Arg (SR) at positions beta70/71 were present at a significantly elevated frequency in sheep with lymphoma as compared with the healthy carriers, which indicated that OLA-DRB1 alleles encoding the SR motif might be positively related to susceptibility to tumor development. The two amino acids in these motifs line a pocket that accommodates the side chain of a bound peptide according to a model of the crystal structure of human leukocyte antigen (HLA)-DR1. To analyze immunoreactions of sheep with alleles that encoded RK or SR at beta70/71, we selected sheep with either the RK/SR genotypes or the SR/SR genotypes and immunized them with a mixture of multiple synthetic antigenic peptides that corresponded to T-helper, T-cytotoxic, and B-cell epitopes of the BLV envelope glycoprotein gp51. Two weeks after the last immunization, all of the sheep were challenged with BLV. Sheep with the RK/SR genotype produced neutralizing antibodies against BLV; they eliminated BLV completely within 28 weeks of the BLV challenge, and they gave strong lymphocyte-proliferative responses to the peptides used for immunization. Moreover, such animals did not develop lymphoma. By contrast, sheep with the SR/SR genotype continued to produce BLV throughout the experimental period and developed terminal disease. Our results indicate that the differences in immunoresponse were due to differences in major histocompatibility complex class II alleles and reflected the risk of BLV-induced leukemogenesis. In addition, it appears that susceptibility to tumor development may be determined to some extent by polymorphic residues binding to antigenic peptides directly within the binding cleft of the OLA-DR molecule.  (+info)

Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. (7/6021)

CYP1B1-null mice, created by targeted gene disruption in embryonic stem cells, were born at the expected frequency from heterozygous matings with no observable phenotype, thus establishing that CYP1B1 is not required for mouse development. CYP1B1 was not detectable in cultured embryonic fibroblast (EF) or in different tissues, such as lung, of the CYP1B1-null mouse treated with the aryl hydrocarbon receptor agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin whereas the equivalent wild-type EF cells express basal and substantial inducible CYP1B1 and lung expresses inducible CYP1B1. CYP1A1 is induced to far higher levels than CYP1B1 in liver, kidney, and lung in wild-type mice and is induced to a similar extent in CYP1B1-null mice. 7,12-dimethylbenz[a]anthracene (DMBA) was toxic in wild-type EFs that express CYP1B1 but not CYP1A1. These cells effectively metabolized DMBA, consistent with CYP1B1 involvement in producing the procarcinogenic 3,4-dihydrodiol as a major metabolite, whereas CYP1B1-null EF showed no significant metabolism and were resistant to DMBA-mediated toxicity. When wild-type mice were administered high levels of DMBA intragastrically, 70% developed highly malignant lymphomas whereas only 7.5% of CYP1B1-null mice had lymphomas. Skin hyperplasia and tumors were also more frequent in wild-type mice. These results establish that CYP1B1, located exclusively at extrahepatic sites, mediates the carcinogenicity of DMBA. Surprisingly, CYP1A1, which has a high rate of DMBA metabolism in vitro, is not sufficient for this carcinogenesis, which demonstrates the importance of extrahepatic P450s in determining susceptibility to chemical carcinogens and validates the search for associations between P450 expression and cancer risk in humans.  (+info)

Can we cure indolent lymphomas? (8/6021)

The current consensus is that indolent lymphomas are incurable disorders. There are some indications that these malignancies are potentially curable. Indeed, not all indolent lymphomas are currently incurable. For example, patients with Ann Arbor stage I-II indolent lymphomas can experience long-term disease-free survival and probable cure. Also, from the available literature data, it seems that the achievement of a molecular complete remission is a desirable objective. Patients who achieve a persistently negative PCR state seldom relapse, whereas the opposite is true for persistently positive cases. In view of its excellent correlation with disease-free survival when examined serially in multiple blood or marrow samples, the PCR technique has the potential of providing a tumor marker that can be used as an early end point for clinical trials. By serving as an early surrogate end point, PCR could play an important role in expediting the development of new treatment strategies. Whether IFN is capable of increasing the molecular complete remission rate as measured by PCR is not known. However, it is clear that from the clinical standpoint, IFN has been able to increase 2-fold the length of remission in patients with advanced indolent lymphomas. In at least two studies, this has been associated with prolongation of survival. More intensive regimens such as alternating triple therapy, when used in combination with IFN, seem to have improved the quality of remissions as judged by the PCR assay. Finally, the site where the bcl-2 breakpoint occurs seems to have clinical significance. Those follicular lymphomas with germ-line bcl-2, in our experience, have behaved more aggressively than the others, and their failure-free survival seems different from the usual indolent lymphomas and more closely resembles the large cell lymphomas. Although the biological significance of this observation is not yet understood, this group might actually constitute a prognostically different subset with a more aggressive and perhaps more curable lymphoma. Whether the plateau observed in their failure-free survival curve will be maintained with more follow-up and whether they might be a curable subset remain to be determined.  (+info)

Lymphoma is cancer of the lymphatic_system. Lymphoma is broken down into two major types: hodgkins_disease and non-Hodgkins lymphoma. Various Types of Lymphoma (Not inclusive): adult T-cell lymphoma , adult T-cell leukemia/lymphoma see under leukemia. B-cell lymphoma any in a large group of non-Hodgkins lymphomas characterized by malignant transformation of the B lymphocytes. B-cell monocytoid lymphoma a low-grade lymphoma in which cells resemble those of hairy cell leukemia. Burkitts lymphoma a form of small noncleaved-cell lymphoma, usually occurring in Africa, manifested usually as a large osteolytic lesion in the jaw or as an abdominal mass; Epstein-Barr virus has been implicated as a causative agent. centrocytic lymphoma mantle cell l. convoluted T-cell lymphoma lymphoblastic lymphoma with markedly convoluted nuclei. cutaneous T-cell lymphoma a group of lymphomas exhibiting (1) clonal expansion of malignant T lymphocytes arrested at varying stages of differentiation of cells committed to ...
PRIMARY OBJECTIVES:. I. To determine the safety, toxicity, and maximum tolerated dose of lenalidomide when combined with temsirolimus in patients with relapsed lymphomas. (Phase I) II. To determine complete and overall response rate of lenalidomide plus temsirolimus in patients with relapsed lymphomas as stratified by histology: follicular lymphoma, diffuse large B-cell lymphoma, and lymphoma not otherwise specified (NOS) (including Hodgkin lymphoma, T-cell non-Hodgkin lymphoma [T-NHL], lymphoplasmacytic lymphoma, and mantle cell lymphoma). (Phase II) III. To determine duration of response, progression-free survival, and overall survival of lenalidomide plus temsirolimus in patients with relapsed lymphomas as stratified by histology: diffuse large B-cell lymphoma, follicular lymphoma, and lymphoma NOS (including Hodgkin lymphoma, T-NHL, lymphoplasmacytic lymphoma, mantle cell lymphoma). (Phase II). SECONDARY OBJECTIVES:. I. To determine mammalian target of rapamycin (mTOR) pathway activation in ...
PRIMARY OBJECTIVES:. I. To determine the safety, toxicity, and maximum tolerated dose of lenalidomide when combined with temsirolimus in patients with relapsed lymphomas. (Phase I) II. To determine complete and overall response rate of lenalidomide plus temsirolimus in patients with relapsed lymphomas as stratified by histology: follicular lymphoma, diffuse large B-cell lymphoma, and lymphoma not otherwise specified (NOS) (including Hodgkin lymphoma, T-cell non-Hodgkin lymphoma [T-NHL], lymphoplasmacytic lymphoma, and mantle cell lymphoma). (Phase II) III. To determine duration of response, progression-free survival, and overall survival of lenalidomide plus temsirolimus in patients with relapsed lymphomas as stratified by histology: diffuse large B-cell lymphoma, follicular lymphoma, and lymphoma NOS (including Hodgkin lymphoma, T-NHL, lymphoplasmacytic lymphoma, mantle cell lymphoma). (Phase II). SECONDARY OBJECTIVES:. I. To determine mammalian target of rapamycin (mTOR) pathway activation in ...
Looking for primary lymphoma of the brain? Find out information about primary lymphoma of the brain. in the United States, a preliminary election in which the candidate of a party is nominated directly by the voters. The establishment of the primary system... Explanation of primary lymphoma of the brain
TY - JOUR. T1 - Molecular profiling reveals prognostically significant subtypes of canine lymphoma. AU - Frantz, A. M.. AU - Sarver, A. L.. AU - Ito, D.. AU - Phang, T. L.. AU - Karimpour-Fard, A.. AU - Scott, M. C.. AU - Valli, V. E O. AU - Lindblad-Toh, K.. AU - Burgess, K. E.. AU - Husbands, B. D.. AU - Henson, M. S.. AU - Borgatti, A.. AU - Kisseberth, W. C.. AU - Hunter, L. E.. AU - Breen, M.. AU - OBrien, T. D.. AU - Modiano, Jaime F.. PY - 2013/8/1. Y1 - 2013/8/1. N2 - We performed genomewide gene expression analysis of 35 samples representing 6 common histologic subtypes of canine lymphoma and bioinformatics analyses to define their molecular characteristics. Three major groups were defined on the basis of gene expression profiles: (1) low-grade T-cell lymphoma, composed entirely by T-zone lymphoma; (2) high-grade T-cell lymphoma, consisting of lymphoblastic T-cell lymphoma and peripheral T-cell lymphoma not otherwise specified; and (3) B-cell lymphoma, consisting of marginal B-cell ...
Thyroid lymphoma diagnosis (costs for program #222877) ✔ University Hospital Tubingen ✔ Department of Internal Medicine: oncology, hematology, gastroenterology, cardiology, infectology ✔ BookingHealth.com
Thyroid lymphoma diagnosis (costs for program #142769) ✔ Academic Hospital Schwabing ✔ Department of Pediatrics ✔ BookingHealth.com
Lymphomas are any cancers of the lymphatic tissues. They are distinguished/classified by the World Health Organization (WHO) system, using the latest information on the appearance and growth pattern of the lymphoma cells and genetic features, including whether or not it is a Hodgkin lymphoma, a T-cell or B-cell lymphoma, and the site from which the lymphoma arises.. Hodgkin lymphoma is marked by the presence of a type of cell called the Reed-Sternberg cell.. Non-Hodgkin lymphomas, which are defined as being all lymphomas except Hodgkin lymphoma, are more common than Hodgkin lymphoma. A wide variety of lymphomas are in this class, and the causes, the types of cells involved, and the prognosis vary by type. The incidence of non-Hodgkin lymphoma increases with age. It is further divided into several subtypes ...
Define malignant lymphoma (mixed cell). malignant lymphoma (mixed cell) synonyms, malignant lymphoma (mixed cell) pronunciation, malignant lymphoma (mixed cell) translation, English dictionary definition of malignant lymphoma (mixed cell). n. pl. lym·pho·ma·ta or lym·pho·mas 1. Any of various malignant tumors that arise from the lymphocytic cells of the immune system. 2. Any of various cancers...
Central nervous system (CNS) lymphoma is a condition in which malignant cells are present in the lymph tissue of the brain and/or spinal cord. Treatment for CNS lymphoma generally does not include surgery. Instead, nonsurgical treatments, namely corticosteroids, chemotherapy and/or whole-brain radiation therapy, are used to treat CNS lymphoma.. Lymphoma designates a group of cancers that arise from white blood cells called lymphocytes. Because lymphocytes travel in the blood and lymph tissue and pass in and out of the CNS, lymphoma too can develop in various places in the body, including the CNS. CNS lymphoma is an aggressive type of lymphoma.. CNS lymphoma comes in two forms, depending on the origin of the tumor, and can produce single or multiple growths. ...
Lymphoma is typically a solid tumor of mature white blood cells in lymphoid tissue. The major clinical and pathological subtypes of adulthood lymphoma include follicular lymphoma and diffuse large B-cell lymphoma. However, the World Health Organization recognizes 70 different forms of lymphoma. Lymphomas typically affect the lymph nodes, unlike leukemia, which affects the bone marrow. The molecular and biological pathways responsible for cell adhesion, cell cycle, PI-3-Kinase/AKT signaling, and T cell differentiation are dysregulated during lymphoma. Dysregulated gene expression, mutations, and differentially methylated promoters are routinely detected in molecular analyses of lymphoma samples. Analyzing and monitoring these affected pathways may lead to a better understanding of the molecular mechanisms behind lymphoma development, classification, and therapeutic response ...
Treatment varies depending on the exact type of B or T-cell lymphoma you have, where it has spread in your body and how fast it is likely to grow. Your age and your general health are also taken into account. When deciding how to treat your lymphoma it is important to know how fast it is likely to grow and cause problems in your body. This is called the grade of your lymphoma.. Some types of lymphoma grow slowly, cause few symptoms and may not need to be treated urgently. These are known as indolent lymphomas (also called low-grade lymphomas). Others grow more quickly, cause more severe symptoms and generally need to be treated soon after they are diagnosed. These are known as aggressive lymphomas (also called intermediate-grade and high-grade lymphomas).. Low-grade lymphomas (indolent). Many low-grade lymphomas take years to grow, cause few if any symptoms and do not necessarily need to be treated initially. In these cases the doctor may recommend regular checkups to carefully monitor your ...
Serum protein electrophoresis was performed in 63% of 1,069 consecutive patients with lymphoma. No monoclonal peaks of IgM specificity were found in sera from 345 patients with nodular lymphoma or Hodgkins disease. Of the remaining 333 patients with diffuse lymphoma, 1.5% had an IgG peak, suggesting a coincidental relationship of IgG peaks to lymphoma. IgM peaks occurred in 3.6% of patients with diffuse lymphoma, a prevalence about 60 times more frequent than that in normal subjects. Such peaks were more frequent in older patients, suggesting an increased incidence of lymphomas producing monoclonal macroglobulins with advancing age. There was a close correlation between lymphoma mass and the level of the IgM peak in individual patients. Results supported the value of identifying monoclonal components in all patients with lymphoma, particularly those with diffuse lymphocytic infiltration. ...
Lymphomas. Lymphoma is a type of cancer that originates in cells of the lymphatic system. There are many types of lymphomas; however, these tumors are commonly divided into two main categories: Hodgkins and Non-Hodgkins Lymphomas.. Lymphomas are curable if detected early and treatments are well tolerated. Historically, Non-Hodgkins Lymphomas were one of the first cancers cured with Radiation Therapy alone due to its radiation sensitivity.. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These sub-types behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.. Lymphomas Treatment. The management of lymphoma requires a multidisciplinary team as the efforts of the surgeon, the hematologist, and the radiation oncologist must interact in the management of ...
PASCUAL, Marta et al. Primary lymphoma of the colon. Rev. esp. enferm. dig. [online]. 2013, vol.105, n.2, pp.79-83. ISSN 1130-0108. http://dx.doi.org/10.4321/S1130-01082013000200003.. Background: primary colorectal lymphoma is a very rare disease, representing less than 0.5 % of all primary colorectal neoplasms. The gastrointestinal tract is the most frequently involved site of all extranodal lymphomas, the most common type of that is non-Hodgkins lymphoma. Early diagnosis is often difficult because of unspecific symptoms. Therapeutic approaches have classically included radical resection, chemotherapy and radiotherapy. Materials and methods: we present our experience in the management of primary colorectal lymphomas over a 17-year period (1994-20011). Results: in this period 7 cases of primary colorectal lymphoma were diagnosed in our institution. Abdominal pain and change in bowel habit were the most frequent symptoms. Five patients underwent emergency surgery because of bleeding or bowel ...
This is Part III of three lengthily posts involving autoimmune diseases and lymphomas. In the Part I post, I focused on a particular autoimmune disease, Lupus erythematosus, its genetic causes and new therapies intended to address it. The Part II post was concerned with the association between Lupus and other autoimmune diseases with lymphomas, what this association is telling us, and the key role of inflammation. Further, I discussed the key role of NF-kappaB, a cell nuclear factor, in autoimmune-related inflammation. This Part III post focuses on lymphomas, their classification, causes, and conventional and emerging therapies for lymphomas. Finally, I include a few comments and speculations about where lymphoma treatments may be going.. Classifications of lymphomas. Lymphoma is a class of cancers that originates in lymphocytes (particularly, T cells and B cells) of the immune system(ref). One such cancer is Hodgkins disease, named after the person who discovered it, and there are 16 other ...
Lymphoma is a form of cancer that affects the immune system. Consult with the experts at NorthShore to learn about lymphoma diagnosis and treatment.
CASE REPORT. Primary pancreatic lymphoma in an HIV patient: Dilemmas in diagnosis and management. E. LootsI; F. AndersonII; S. R. ThomsonIII. IF.C.S. (S.A.) Department of General Surgery, Addington Hospital and Nelson R. Mandela School of Medicine, University of Natal, Durban ...
High grade aggressive lymphomas have high mortality. By their nature, more than 40% of patients die from these diseases even with the improved treatment strategies currently available for oncology patients. The characteristic feature is that they are functionally heterogeneous and therefore have different biological and molecular signatures which make it difficult for all groups to respond to same line of treatment. Based on the above, I set out to look at the impact of viral and cellular gene products on these groups of diseases: In chapter 3 I developed monoclonal antibodies against HERV‐K10. I subsequently investigated their expressions in aggressive lymphomas including Diffuse Large B‐cell lymphoma, Hodgkins lymphoma and Primary CNS lymphomas. I showed HERV‐K10 is expressed in cell lines of aggressive lymphomas, but not in paraffin‐embedded tissues. In chapter 4 I showed that the expression of ATM using immune‐histochemistry techniques in aggressive lymphomas does offer a guide to ...
Lymphoma is a type of cancer that originates in lymphocytes (a type of white blood cell in the vertebrate immune system). There are many types of lymphoma. Lymphomas are part of the broad group of diseases called hematological neoplasms. It was discovered by Thomas Hodgkin in 1832 and was called Hodgkins Disease throughout the 19th and 20th centuries. Colloquially, lymphoma is broadly categorized as Hodgkins lymphoma or non-Hodgkin lymphoma (all other types of lymphoma). Scientific classification of the types of lymphoma is more detailed. Although older classifications referred to histiocytic lymphomas, these are recognized in newer classifications as of B, T or NK cell lineage. Histiocytic malignancies are rare and are classified as sarcomas.[1] ...
Non-Hodgkin lymphomas are frequent tumors. However, extraglandulary forms are very unusual, and the location in the uterine cervix is also extraordinary. A case of an elderly woman with symptoms not related with the tumor, in whom the diagnosis was made from the incidental finding of a distended obstructive bladder is presented.. Pelvic mass is one of the forms of presentation of primary malignant lymphomas of the uterine cervix. Diagnosis was made in this case by transvaginal biopsy under general anesthesia. Biopsy showed a diffuse T-cell lymphoma, a very rare finding considering that most of published cases are B-cell type.. The importance of distinguishing malignant lymphoma from undifferentiated carcinoma or sarcoma is emphasized since cervical malignant lymphoma can be successfully treated with irradiation.. CITATION An Med Interna. 2000 Aug;17(8):432-3. ...
Certain autoimmune and chronic inflammatory conditions, such as Sjögrens syndrome and rheumatoid arthritis (RA), have consistently been associated with an increased risk of malignant lymphomas, but it is unclear whether elevated lymphoma risk is a phenomenon that accompanies inflammatory conditions in general. Likewise, it is debated whether the increased risk identified in association with some disorders pertains equally to all individuals or whether it varies among groups of patients with different phenotypic or treatment-related characteristics. It is similarly unclear to what extent the increased lymphoma occurrence is mediated through specific lymphoma subtypes. This update reviews the many findings on risks, risk levels, and lymphoma characteristics that have been presented recently in relation to a broad range of chronic inflammatory, including autoimmune, conditions. Recent results clearly indicate an association between severity of chronic inflammation and lymphoma risk in RA and ...
OBJECTIVE: Patients with primary Sjögrens syndrome (SS) are at greater risk of developing lymphoma. This study was undertaken to evaluate whether the Fms-like tyrosine kinase 3 ligand (Flt-3L) might be associated with lymphoma in primary SS. METHODS: Serum levels of Flt-3L were measured in 369 patients with primary SS from the French Assessment of Systemic Signs and Evolution of Sjögrens Syndrome study cohort and in 10 patients with primary SS at the time of lymphoma diagnosis in an Italian cohort. Associations between increased levels of Flt-3L and a history of lymphoma, history of previously diagnosed criteria related to a high risk of lymphoma, and greater extent of disease activity were evaluated. RESULTS: Among patients with primary SS, higher levels of Flt-3L were significantly associated with a history of lymphoma (P = 0.0001). Previous markers for risk of lymphoma development, such as presence of purpura, low levels of C4, presence of lymphocytopenia, low levels of IgM, high levels of β2
TUESDAY, Oct. 20, 2020 (HealthDay News) -- Actor Jeff Bridges announced on Monday that he has been diagnosed with lymphoma.. Telling his fans on Twitter, the acclaimed thespian said, Although it is a serious disease, I feel fortunate that I have a great team of doctors and the prognosis is good. Im starting treatment and will keep you posted on my recovery.. According to the U.S. Centers for Disease Control and Prevention, lymphoma is a cancer that affects the lymph system, or tissues and organs that produce, store and carry white blood cells that fight infections. There are two kinds of lymphoma: Hodgkin and non-Hodgkin lymphoma (NHL).. Treatment of lymphoma usually involves chemotherapy, immunotherapy, radiation therapy, a bone marrow transplant or some combination of these, explained Dr. Wasif Saif, deputy physician-in-chief and medical director at Northwell Health Cancer Institute, in Lake Success, N.Y.. A specialized treatment called chimeric antigen receptor (CAR)-T cell therapy is ...
TUESDAY, Oct. 20, 2020 (HealthDay News) -- Actor Jeff Bridges announced on Monday that he has been diagnosed with lymphoma.. Telling his fans on Twitter, the acclaimed thespian said, Although it is a serious disease, I feel fortunate that I have a great team of doctors and the prognosis is good. Im starting treatment and will keep you posted on my recovery.. According to the U.S. Centers for Disease Control and Prevention, lymphoma is a cancer that affects the lymph system, or tissues and organs that produce, store and carry white blood cells that fight infections. There are two kinds of lymphoma: Hodgkin and non-Hodgkin lymphoma (NHL).. Treatment of lymphoma usually involves chemotherapy, immunotherapy, radiation therapy, a bone marrow transplant or some combination of these, explained Dr. Wasif Saif, deputy physician-in-chief and medical director at Northwell Health Cancer Institute, in Lake Success, N.Y.. A specialized treatment called chimeric antigen receptor (CAR)-T cell therapy is ...
TUESDAY, Oct. 20, 2020 (HealthDay News) -- Actor Jeff Bridges announced on Monday that he has been diagnosed with lymphoma.. Telling his fans on Twitter, the acclaimed thespian said, Although it is a serious disease, I feel fortunate that I have a great team of doctors and the prognosis is good. Im starting treatment and will keep you posted on my recovery.. According to the U.S. Centers for Disease Control and Prevention, lymphoma is a cancer that affects the lymph system, or tissues and organs that produce, store and carry white blood cells that fight infections. There are two kinds of lymphoma: Hodgkin and non-Hodgkin lymphoma (NHL).. Treatment of lymphoma usually involves chemotherapy, immunotherapy, radiation therapy, a bone marrow transplant or some combination of these, explained Dr. Wasif Saif, deputy physician-in-chief and medical director at Northwell Health Cancer Institute, in Lake Success, N.Y.. A specialized treatment called chimeric antigen receptor (CAR)-T cell therapy is ...
Malignant lymphomas are a diverse group of cancers derived from the immune system, which result from neoplastic proliferation of B or T lymphocytes. These tumors may arise anywhere in the physique, most commonly inside lymph nodes but occasionally in other organs in which lymphoid components reside. 1 subtype of lymphomas that are composed of mixtures of cellular kinds having a unique biology is called Hodgkins lymphomas, whereas all other kinds of lymphomas are referred to as non-Hodgkins lymphomas.. Several elements are associated with the improvement of non-Hodgkins lymphoma. These consist of congenital or acquired immunodeficiency states for example AIDS or iatrogenic immunosuppression utilized in organ transplantation. Viruses are related to the pathogenesis of some types. For instance, most instances of Burkitts lymphoma that happen in Africa (endemic kind) are associated with Epstein-Barr virus (EBV), whereas Burkitts lymphoma manifesting in temperate zones is associated with EBV in ...
September is Lymphoma month and this Sunday 15 September is World Lymphoma Awareness Day. Lymphoma is cancer of the lymphatic system and every year more than 5,000 Australians are diagnosed with it.. To help raise awareness of Lymphoma the nurses on ward 44 at Monash Medical Centre Clayton wore lime today and hosted a Lymphoma in the Limelight afternoon tea to help to fund Lymphoma Care Nurses across Australia.. The team were joined by very special guest Sharon Millman, Lymphoma Australias CEO Lymphoma Australia would like to say a huge thank you to the team on ward 44 at Monash hospital for turning Lime for Lymphoma to acknowledge World Lymphoma Awareness Day said Sharon.. The team are now in an online competition against other Australian Hospitals to be crowned the most supportive and creative team to host a Lymphoma in the Limelight afternoon tea. ...
Immune serums prepared in rabbits with antigens made from normal mouse organs and tissues that were presumably devoid of large numbers of lymphocytic cells (notably kidney, liver, brain, whole embryos, and erythrocytes) proved lethal for the cells of several transplanted mouse lymphomas in vitro in the presence of complement; but these immune serums, when given intraperitoneally in large amounts to susceptible mice that had been implanted subcutaneously with lymphoma cells of one or another of several types, failed entirely to inhibit growth of the lymphoma cells in vivo. In contrast, immune serums made with cells procured from transplanted mouse lymphomas as antigens, and those made with cells from normal mouse thymus or lymph nodes, acted even more powerfully upon the several types of lymphoma cells in vitro than did the immune serums prepared with normal mouse organs, and when given intraperitoneally to implanted mice they brought about death of the lymphoma cells in vivo, the effect being to ...
Low-grade lymphomas are typically made up of small, slow-growing cells. Faster-growing (high-grade) cells can develop. As the proportion of larger, faster-growing lymphoma cells increases, the lymphoma begins to behave more like a faster-growing high-grade lymphoma. This process is known as transformation.. Transformation is important because you need a different type of treatment if your lymphoma becomes faster growing.. To learn more about transformed lymphoma or to download or fact sheet please click here Transformed Lymphoma ...
Hodgkins disease was the primary lymphoma to be defined as early as 1832 by Prof. Hodgkins. Over the years, non-Hodgkins lymphoma has become quite common. In the United States, it is estimated that 69,000 new cases and 19,000 deaths from non-Hodgkins lymphoma will occur yearly. It has not been pursued in detail as of now, and there are many points still in the dark.. Many doctors adopt a waiting policy where they inspect the patient patiently before coming to a practical conclusion. It is diagnosed (Understanding a Lymphoma Diagnosis) by biopsy through needle insertion. In severe manifestations, the whole part containing affected lymph nodes needs to be taken out. A combination treats it of radiation and chemotherapy. The logic is to retain the white blood cells to grow and multiply. Since it is an immune system-specific disease, immunotherapy or boosting the immune system is deemed the best antidote.. Stem cell transplant that has its precepts on DNA strands is also quite active but highly ...
OBJECTIVE: To describe cases of lymphoma associated with anti-TNF therapy, identify risk factors, estimate the incidence and compare the risks for different anti-TNF agents. METHODS: A national prospective registry was designed (Research Axed on Tolerance of bIOtherapies; RATIO) to collect all cases of lymphoma in French patients receiving anti-TNF therapy from 2004 to 2006, whatever the indication. A case-control analysis was conducted including two controls treated with anti-TNF per case and an incidence study of lymphoma with the French population was used as the reference. RESULTS: 38 cases of lymphoma, 31 non-Hodgkins lymphoma (NHL) (26 B cell and five T cell), five Hodgkins lymphoma (HL) and two Hodgkins-like lymphoma were collected. Epstein-Barr virus was detected in both of two Hodgkins-like lymphoma, three of five HL and one NHL. Patients receiving adalimumab or infliximab had a higher risk than those treated with etanercept: standardised incidence ratio (SIR) 4.1 (2.3-7.1) and 3.6 (2.3-5.6
The Eighth Annual Round It Up for Lymphoma Campaign Raises Critical Funds for the Lymphoma Research Foundation and The University of Chicago Medicine Biobank. The Lymphoma Research Foundation is proud to announce cause marketing partner, Highland Ventures, Ltd will return with its Round It Up for Lymphoma fundraising campaign. The campaign will run from March 6 to March 22, 2020.. Customers of Family Video, Marcos Pizza and StayFit24 will have the opportunity to support cancer research and education by rounding up their purchases to the nearest dollar, participating in fundraising events at their local retail locations or donating directly online at familyvideo.com/round-it-up. One hundred percent of the proceeds raised through the campaign will support the Lymphoma Research Foundation and the University of Chicago Medicine Biobank. Since inception, Round It Up for Lymphoma has raised more than $8.5 million.. Our mission to eradicate lymphoma can only be realized with greater investment in ...
What is lymphoma?. Lymphoma is a cancer of the cells of the immune system called lymphocytes. Lymphocytes are present throughout the body, so dogs can develop lymphoma in multiple organs. Lymphoma most often affects lymph nodes, but can also affect the liver, spleen, bone marrow, and other sites.. Lymphoma is typically diagnosed using aspirates collected from enlarged lymph nodes. In some cases, diagnosis may require sampling of bone marrow or other organs, tissue biopsy, or molecular testing (flow cytometry, PARR). Once a diagnosis is made, staging tests are recommended to assess the extent of disease. Complete staging includes blood and urine testing, non-invasive imaging (chest X-rays, abdominal ultrasound), and additional aspirates. This evaluation provides prognostic information, a baseline for monitoring, and information regarding organ function and involvement. Results may influence treatment recommendations or help anticipate potential complications.. Lymphoma is categorized into five ...
Background Several studies have suggested an association between occupational exposure to solvents and lymphoma risk. However, findings are inconsistent and the role of specific chemicals is not known.. Objective To investigate the role of occupational exposure to organic solvents in the aetiology of B-cell non-Hodgkins lymphoma (B-NHL) and its major subtypes, as well as Hodgkins lymphoma and T-cell lymphoma.. Methods 2348 lymphoma cases and 2462 controls participated in a case-control study in six European countries. A subset of cases were reviewed by a panel of pathologists to ensure diagnostic consistency. Exposure to solvents was assessed by industrial hygienists and occupational experts based on a detailed occupational questionnaire.. Results Risk of follicular lymphoma significantly increased with three independent metrics of exposure to benzene, toluene and xylene (BTX) (combined p=4×10−7) and to styrene (p=1×10−5), and chronic lymphocytic leukaemia (CLL) risk increased with ...
Introduction:. Lymphoma of the stomach is an uncommon tumor. However, it is the most common extra-nodal manifestation of Non-Hodgkin lymphoma. Over the last few decades, preferred treatment for gastric lymphoma has shifted from surgical resection to non-surgical methods involving chemotherapy and RT. The current standard treatment is chemo-immunotherapy. The role of RT and surgery, if any, is unclear.. Methods:. We reviewed data which was obtained from the Surveillance, Epidemiology and End Results (SEER) data registry for patients with gastric lymphoma from 1973 until 2011. The data was analyzed using Microsoft Excel and statistical analysis was performed using SPSS statistical software. The SEER registry does not provide information about chemotherapy (CT) administered.. Results:. We analyzed 13,659 patients with the diagnosis of gastric lymphoma in the SEER database. The three most prevalent subtypes were diffuse large B-cell lymphoma (DLBCL) with 6,134 (44.9%) cases, extranodal marginal zone ...
The Gray-Zone Lymphomas represent histological entities that are interposed between Hodgkins lymphoma and Non-Hodgkins Lymphoma. We report the case of a man diagnosed with a Lymphoma B unclassifiable with intermediate characteristics between Hodgkins lymphoma and a large cell lymphoma B, with a rare spinal localization. We decided to treat him with Adriamycin, Bleomycin, Vinblastine, Dacarbazine and anti-CD20 antibody, achieving a complete response. We here discuss histopathologic patterns, and work-up of this pathological entity, and we demonstrated that more intensive therapy do not always correlate with better therapeutic goals, inviting to analyze each case.. ...
Gentaur molecular products has all kinds of products like :search , Alpha Dia \ Human Non_Hodgkins lymphoma Tumor lysate \ HCL-1332 for more molecular products just contact us
Lymphoma is a kind of bbathroom toiletd most cancers that affects the lymphocyte cell phones that play a job within the immune device, and essentially regives cells thinking about the lymphatic gadget of the frame. Lymphomas are of 2 sorts: Hodgkin lymphoma, which advancelaystation from atypical B lymphocyte cells; and Non-Hodgkin lymphoma, which enhancelaystation from both unusual B or T lymphocyte cells, and which is outstandingby means of distinctive gewebic markers. Tlisted here are 5 sub-forms of Hodgkin lymphoma and about threezero sub-forms of Non-Hodgkin lymphoma. vintage age; an infections; scientific stipulations which compromenadeise the immune machine; publicityto poisonous chemical compounds; and a circle of relatives historical past, are chance issue s for this situation. commonplace symptomsinclude acheless and enmassived lymph nodes, spleen enhugement, fever, chunwells, unprovide an explanation fored weight reduction, night time sweats, drainedness and that itching. ...
Lymphoma is cancer of the lymphatic system. Generally, lymphoma cells grow in lymph glands (nodes). This causes the glands to get bigger or swell. There are two types of lymphoma. One is called Hodgkin and the other is non-Hodgkin lymphoma. The difference between the two types depends on the appearance of the lymphoma cells under the microscope. Most lymphomas are non-Hodgkin lymphomas. ...
TY - JOUR. T1 - LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma. AU - Lossos, Chen. AU - Bayraktar, Soley. AU - Weinzierl, Elizabeth. AU - Younes, Sheren F.. AU - Hosein, Peter. AU - Tibshirani, Robert J.. AU - Sutton Posthumus, Jocelyn. AU - Deangelis, Lisa M.. AU - Raizer, Jeffrey. AU - Schiff, David. AU - Abrey, Lauren. AU - Natkunam, Yasodha. AU - Lossos, Izidore. PY - 2014/1/1. Y1 - 2014/1/1. N2 - Primary central nervous system lymphoma (PCNSL) is an aggressive sub-variant of non-Hodgkin lymphoma (NHL) with morphological similarities to diffuse large B-cell lymphoma (DLBCL). While methotrexate (MTX)-based therapies have improved patient survival, the disease remains incurable in most cases and its pathogenesis is poorly understood. We evaluated 69 cases of PCNSL for the expression of HGAL (also known as GCSAM), LMO2 and BCL6 - genes associated with DLBCL prognosis and pathobiology, and analysed their correlation to survival in 49 PCNSL patients ...
TY - JOUR. T1 - The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. AU - Larocca, Luigi Maria. AU - Capello, Daniela. AU - Rinelli, Alessandro. AU - Nori, Simonetta. AU - Antinori, Andrea. AU - Gloghini, Annunziata. AU - Cingolani, Antonella. AU - Migliazza, Anna. AU - Saglio, Giuseppe. AU - Cammilleri-Broet, Sophie. AU - Raphael, Martine. AU - Carbone, Antonino. AU - Gaidano, Gianluca. PY - 1998/8/1. Y1 - 1998/8/1. N2 - Primary central nervous system lymphoma (PCNSL) is a major cause of morbidity and mortality among human immunodeficiency virus (HIV)-infected individuals. The precise histogenetic derivation and the molecular pathogenesis of PCNSL is poorly understood. In an attempt to clarify the histogenesis and pathogenesis of these lymphomas, 49 PCNSL (26 acquired immunodeficiency syndrome [AIDS]-related and 23 AIDS-unrelated) were ...
TY - JOUR. T1 - Primary central nervous system lymphoma. T2 - Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy. AU - Dabaja, Bouthaina S.. AU - McLaughlin, Peter. AU - Ha, Chul S.. AU - Pro, Barbara. AU - Meyers, Christina A.. AU - Seabrooke, Lee F.. AU - Wilder, Richard B.. AU - Kyritsis, Athanassios P.. AU - Preti, H. Alejandro. AU - Yung, W. K.Alfred. AU - Levin, Victor. AU - Cabanillas, Fernando. AU - Cox, James D.. PY - 2003/9/1. Y1 - 2003/9/1. N2 - BACKGROUND. The current study was performed to determine the maximum tolerated dose (MTD), toxicity, and outcome of infusional 5 bromo-2′-deoxyuridine (bromodeoxyuridine; BUdR) given with accelerated fractionation whole brain radiation therapy (WBRT) after chemotherapy for the treatment of primary central nervous system lymphoma (PCNSL). METHODS. Twelve patients with untreated and histologically confirmed PCNSL were entered on the study between 1994 and 1996. ...
TY - JOUR. T1 - Impact of maintenance rituximab on duration of response in primary central nervous system lymphoma. AU - Ambady, Prakash. AU - Fu, Rongwei. AU - Szidonya, Laszlo. AU - Peereboom, David M.. AU - Doolittle, Nancy D.. AU - Neuwelt, Edward A.. N1 - Funding Information: This work was supported in part by National Institute of Health Grants CA137488, NS044687, a Veterans Administration Merit Review Grant and the Walter S. and Lucienne Driskill Foundation, all to EAN. Funding Information: This work was supported in part by National Institute of Health Grants CA137488, NS044687, a Veterans Administration Merit Review Grant and the Walter S. and Lucienne Driskill Foundation, all to EAN. Publisher Copyright: © 2020, Springer Science+Business Media, LLC, part of Springer Nature.. PY - 2020/3/1. Y1 - 2020/3/1. N2 - Purpose: The role of maintenance immunotherapy with anti-CD20 monoclonal antibody rituximab in primary central nervous system lymphoma (PCNSL) is unclear. We retrospectively ...
Primary central nervous system lymphoma (PCNSL) starts in the brain, spinal cord, meninges or eyes. Learn about primary central nervous system lymphoma.
TY - JOUR. T1 - International study on low-grade primary central nervous system lymphoma. AU - Jahnke, Kristoph. AU - Korfei, Agnieszka. AU - ONeill, Brian Patrick. AU - Blay, Jean Yves. AU - Abrey, Lauren E.. AU - Martus, Peter. AU - Poortmans, Philip M.P.. AU - Shenkier, Tamara N.. AU - Batchelor, Tracy T.. AU - Neuwelt, Edward A.. AU - Raizer, Jeffrey J.. AU - Schiff, David. AU - Pels, Hendrik. AU - Herrlinger, Ulrich. AU - Stein, Harald. AU - Thiel, Eckhard. PY - 2006/5. Y1 - 2006/5. N2 - Objective: The aim of this study was to characterize the clinical presentation, course, and outcome of low-grade primary central nervous system lymphoma. Methods: Cases were assessed in a retrospective series collected from 18 cancer centers in 5 countries. Results: Forty patients (18 men, 22 women; median age, 60 years [range, 19-78]) were identified. Involvement of a cerebral hemisphere or deeper brain structures was seen in 37 patients, only leptomeningeal involvement in 2 patients, and spinal cord ...
TY - JOUR. T1 - Case report. T2 - Disorder of excessive somnolence due to central nervous system lymphoma. AU - Lesser, R. P.. AU - St Louis, P.. AU - Dinner, D. S.. AU - Hanson, M.. AU - Little, J. R.. AU - Slugg, P. H.. PY - 1983/1/1. Y1 - 1983/1/1. N2 - We report a patient who developed confusion and recurrent daytime episodes of hypersomnolence. His symptoms proved to be due to a diencephalic primary central nervous system lymphoma, implying that a diencephalic defect in some instances may be involved in the pathogenesis of recurrent sleep attacks.. AB - We report a patient who developed confusion and recurrent daytime episodes of hypersomnolence. His symptoms proved to be due to a diencephalic primary central nervous system lymphoma, implying that a diencephalic defect in some instances may be involved in the pathogenesis of recurrent sleep attacks.. UR - http://www.scopus.com/inward/record.url?scp=0020655405&partnerID=8YFLogxK. UR - ...
Central nervous system lymphoma is a rare non-Hodgkin lymphoma in which malignant (cancer) cells from lymph tissue form in the brain and/or spinal cord (primary CNS) or spread from other parts of the body to the brain and/or spinal cord (secondary CNS). Because the eye is so close to the brain, primary CNS lymphoma can also start in the eye (called ocular lymphoma). The cancer can also involve the spinal fluid that bathes the spinal cord and brain. This is called leptomeningeal lymphoma. See Primary Central Nervous System Lymphoma for signs, symptoms and treatments.. ...
TY - JOUR. T1 - Case-based review. T2 - Primary central nervous system lymphoma. AU - Korfel, Agnieszka. AU - Schlegel, Uwe. AU - Johnson, Derek R.. AU - Kaufmann, Timothy J. AU - Giannini, Caterina. AU - Hirose, Takanori. PY - 2017/1/1. Y1 - 2017/1/1. N2 - Primary CNS lymphoma (PCNSL) is a rare diffuse large B-cell lymphoma originating within the central nervous system. The overall incidence of PCNSL is rising, particularly in the elderly population. Immunosuppression is a strong risk factor, but most patients with this tumor are apparently immunocompetent. Diagnosis of PCNSL can be challenging. Non-invasive or minimally invasive tests such as ophthalmological evaluation and spinal fluid analysis may be useful, but the majority of patients require tumor biopsy for definitive diagnosis. Our knowledge concerning optimum treatment of PCNSL is fragmentary due to paucity of adequately sized trials. Most patients are now initially treated with high-dose-methotrexate-based chemotherapy alone, as the ...
Primary central nervous system lymphoma(PCNSL) is a rare kind of non-Hodgkin lymphoma. Rituximab combined with high-dose methotrexate, cytarabine and dexamethasone (R-MAD regimen) were reported effective for PCNSL patients. Rituximab can cause several side effects, including fever, chills and rigors. In this case report, we demonstrate rituximab-induced interstitial pneumonitis in a PCNSL patient who has been treated with R-MAD regimen. The patient recovered after treatment and she remains complete remission after following consolidation chemotherapy. Here is no report of potential fatal complications of Rituximab like interstitial pneumonitis nowadays in PCNSL patients. As Rituximab is widely used, physicians should raise their awareness of this rare complication and detect RTX-ILD in early stage.
The initial intent of this study was to examine the origins of Primary Central Nervous System Lymphoma (PCNSL), a neoplasm whose oncogenesisin immunocompetentpatients is incompletely understood. With growing information regarding the remarkable plasticity of neural stem cells, and establishment of relationships between hematopoietic and neural stem cells, we hypothesized that PCNSL arises from neural stem/progenitor cells rather than lymphocyte precursors from elsewhere in the body. Markers of neural stem cells were chosen for immunohistochemical(IHC) staining of 5 PCNSL cases and all cases contained Sox2 positive cells, whereas 8 of 9 non-CNS B cell lymphomas so stained had no positive cells. Double-staining with Sox2 and CD20, a B-cell marker, showed no co-localization of Sox2 and CD20, and no CD20-positive tumor cells had Sox2 immunopositivity. Staining of 5 metastatic carcinomas and 1 metastatic melanoma revealed a similar pattern of immunopositivityboth regarding sox2 expression and ...
Paraffin sections of surgical and autopsy material from 24 cases of primary CNS lymphoma were examined for the presence of cytoplasmic immunoglobulin by an immunoperoxidase technique. Definite staining for cytoplasmic immunoglobulin was observed in 13 cases, and in eight of these the pattern of staining was consistent with current concepts of monoclonality. In every case the histological diagnosis of malignant lymphoma was confirmed, and cases were subclassified by both the Lukes-Collins and the Rappaport classifications. Morphologically 12 of the 24 cases resembled immunoblastic sarcoma occurring outside the CNS. Other cases showed features of follicular center cell lymphoma or plasmacytoid lymphocytic lymphoma. Of those cases with positive immunoglobulin staining of tumor cells, the majority showed some plasmacytoid features. It was concluded that the primary CNS lymphomas resemble their counterparts occurring outside the CNS, and that at least a proportion are derived from the B lymphocyte. ...
Although meningiomas are among the most frequent intracranial tumors, primary central nervous system lymphoma represents a rare variant of extranodal non-Hodgkin-type lymphoma. Here, we report on a 73-year-old man with 2 suspicious intracerebral lesions. Combined DOTATATE PET/CT identif...read more ...
Population pharmacokinetics of high-dose methotrexate in patients with primary central nervous system lymphoma | A Smarter Pharmacy
Each cell in HIV-associated primary central nervous system lymphoma (PCNSL) harbors latent EBV. Notably, the triggering of TLR9, a key event in HIV pathogenesis, also promotes EBV latency and transformation. We hypothesized that because only a minority of HIV-infected patients develops PCNSL, their B cells exhibit aberrant signaling responses to TLR9 triggering. We found higher levels of IL-6, CD80, and CD86 expression at baseline in B cells of those patients than in B cells of matched controls, whereas TNF-a expression was lower. Notably, on TLR9 triggering with CpG 2006, CD80 and TNF- were up-regulated to a lesser extent in B cells of the former than in those of matched controls. The reduced up-regulation of CD80 might be explained by its higher baseline expression resulting in a more blunted response rather than a specific deficit of the signaling response to TLR9 triggering. However, this cannot explain the blunted TNF- response, which warrants further investigation. Finally, since increased ...
In this article, the authors discuss the principles guiding the use of chemotherapy for primary central nervous system lymphomas.
Fingerprint Dive into the research topics of Diagnosis of primary central nervous system lymphoma: A systematic review of the utility of CSF screening and the role of early brain biopsy. Together they form a unique fingerprint. ...
Information on Primary central nervous system lymphoma, which may include symptoms, causes, inheritance, treatments, orphan drugs, associated orgs, and other relevant data.
Doctors at NYU Langone use blood testing, a neurological exam, and imaging tests to diagnose primary central nervous system lymphoma. Learn more.
Our study, which is the first large scale population based assessment of lymphoma characteristics in coeliac disease, has demonstrated that the association between coeliac disease and malignant lymphomas is not confined to ETTL but includes other types of T cell NHLs and, more importantly, B cell NHLs that constitute the vast majority of malignant lymphomas in the general population. Indeed, ETTL cases comprised only one third of NHL cases and half of all T cell lymphomas in our study, values markedly lower than previously reported.4-8,24 Furthermore, with respect to location, our study indicated that the association was not confined to primary gastrointestinal lymphomas but also included malignant lymphomas outside of the gastrointestinal tract of both the B and T cell phenotype. Few previous studies have classified coeliac disease associated malignant lymphomas using modern immunostaining methods.7,8,11 In one of these, 23 of 24 reviewed cases were ETTL.8 In another, 11 of 13 lymphomas were of ...
The cell of origin of lymphomas arising in the CNS, a site devoid of normal resident lymphoid tissue, has not been determined. Morphological (4) , immunophenotypic (4) , and molecular genetic (5) studies of PCNSL suggest that the cell of origin is related to the GC. Expression of BCL-6 is one feature that suggests a relationship to the GC. The BCL-6 protein is a zinc-finger transcriptional repressor encoded by the BCL-6 gene (12) . It is required for the formation of the GC (13) . In normal lymphoid tissue, there is nuclear expression of the BCL-6 protein almost exclusively by GC B cells. Lymphomas thought to be derived from GC cells, such as follicular lymphoma, also express BCL-6, whereas lymphomas derived from naïve (chronic lymphocytic leukemia and mantle cell lymphoma) or post-GC (marginal zone lymphomas, myeloma) B cells do not (14 , 15) .. Additional immunophenotypic markers that can aid in the characterization of lymphoid cells with respect to stage of B-cell differentiation were ...
View details of top central nervous system lymphoma hospitals in Delhi NCR. Get guidance from medical experts to select best central nervous system lymphoma hospital in Delhi NCR
Non-Hodgkins lymphoma (or NHL) is one of the most common cancers among 9/11 responders and survivors. Turley Hansen has represented many claimants with Non-Hodgkin lymphoma since cancer was added to the list of illnesses covered under the Zadroga Act.. Non-Hodgkins lymphoma, also called non-Hodgkins lymphoma or NHL, is a cancer that originates in your lymph system - the network spread throughout your body to fight diseases. In non-Hodgkins lymphoma, tumors develop from lymphocytes - a type of white blood cell.. Non-Hodgkins lymphoma is more common than the other general type of lymphoma - Hodgkins lymphoma. Many different sub-types of non-Hodgkins lymphoma exist. The most common non-Hodgkins lymphoma sub-types include diffuse large B-cell lymphoma and follicular lymphoma.. ...
AIDS-related lymphoma describes lymphomas occurring in patients with acquired immunodeficiency syndrome (AIDS). A lymphoma is a type of cancer arising from lymphoid cells. In AIDS, the incidences of non-Hodgkins lymphoma, primary cerebral lymphoma and Hodgkins disease are all increased. There are three different varieties of AIDS-related lymphoma: Diffuse large B-cell lymphoma, B-cell immunoblastic lymphoma, and Burkitts lymphoma (small non-cleaved cell lymphoma). The symptoms of AIDS-related lymphoma can include: weight loss, fever, and night sweats. Non-Hodgkins lymphoma (NHL) is present in about 1%-3% of HIV seropositive people at the time of the initial diagnosis of HIV. However, it is believed that such patients have been seropositive for a prolonged period, but have simply not had their infections recognized previously. This is so because immunodysregulation must exist for an extended interval of time, in order for a lymphoproliferative process to evolve in that context. Primary ...
Both Hodgkins lymphoma and non-Hodgkins lymphoma are lymphomas - a type of cancer that begins in a subset of white blood cells called lymphocytes. Lymphocytes are an integral part of your immune system, which protects you from germs.. The main difference between Hodgkins lymphoma and non-Hodgkins lymphoma is in the specific lymphocyte each involves.. A doctor can tell the difference between Hodgkins lymphoma and non-Hodgkins lymphoma by examining the cancer cells under a microscope. If in examining the cells, the doctor detects the presence of a specific type of abnormal cell called a Reed-Sternberg cell, the lymphoma is classified as Hodgkins. If the Reed-Sternberg cell is not present, the lymphoma is classified as non-Hodgkins.. Many subtypes of lymphoma exist, and your doctor will use laboratory tests to examine a sample of your lymphoma cells to determine your specific subtype. Expect to wait a few days to receive results from these specialized tests.. Your type of lymphoma helps ...
Follicular lymphoma is the most common form of low-grade NHL and the second most common type of lymphoma overall diagnosed in the United States. Most follicular lymphoma diagnoses occur in adults over the age of 60, with equal rates of occurrence in male and female individuals; this specific lymphoma is rare in young people.. Follicular lymphoma affects B-cell lymphocytes and is indolent, which means it grows very slowly. Like most lymphomas, follicular lymphoma usually begins in the lymph nodes. The cells can spread into the blood and bone marrow. Other internal organs, including the liver and spleen, may also be affected.. Because follicular lymphoma grows so slowly, doctors may not treat it right away and instead adopt a watchful waiting approach. Over time, some follicular lymphomas transform into an aggressive (fast-growing) diffuse B-cell type of lymphoma, so its important for people with follicular lymphoma to be monitored closely. Learn more about the several treatment options that ...
Looking for online definition of histiocytic lymphoma in the Medical Dictionary? histiocytic lymphoma explanation free. What is histiocytic lymphoma? Meaning of histiocytic lymphoma medical term. What does histiocytic lymphoma mean?
Response:. Our group published a microarray study of primary central nervous system lymphoma (PCNSL) in Blood in March 2008.1 We reported a comprehensive CNS signature of PCNSL, identifying single-gene differential expression as well as a pathway signature. Most notably, our pathway signature for PCNSL is characterized by differential expression of extracellular matrix (ECM)- and adhesion-related pathways. The most up-regulated gene is the ECM- and adhesion-related osteopontin (SPP1). Our study is unique in that we compared PCNSL to a broad spectrum of non-CNS diffuse large B-cell lymphoma (DLBCL), consisting of nodal and extranodal samples; and in-depth bioinformatics analysis was performed. This is in contrast to 2 other microarray studies in PCNSL2,3 in which the comparisons were made to nodal DLBCL and no pathway analysis was performed.. We are pleased that Rubenstein et al have confirmed our single-gene expression findings by retrospective analysis of their data and come up with concordant ...
Lymphomas account for 5% of all cancers in the United States, with Non-Hodgkins lymphoma being far more prevalent than Hodgkins lymphoma. It is estimated that in 2012, 70,130 will be diagnosed with Non-Hodgkins lymphoma and 9,060 will be diagnosed with Hodgkins lymphoma. Further, it is estimated that 18,940 people will die from Non-Hodgkins lymphoma and 1,190 people will die from Hodgkins lymphoma this year. One out of every 47 people will be diagnosed with Non-Hodgkins lymphoma and one out of every 436 people will be diagnosed with Hodgkins lymphoma in their lifetimes. In the US, we spend approximately $10.2 billion annually treating lymphoma.. NCI allocated 2.7% of its annual budget (or $137.0 million) in 2010 for lymphoma research.. The information in this section was also provided to the public courtesy of the NCI. You can find more information about lymphoma in their What You Need to Know About Hodgkins Lymphoma and What You Need to Know About Non-Hodgkins Lymphoma booklets, here and ...
The B-cell lymphomas are types of lymphoma affecting B cells. Lymphomas are blood cancers in the lymph nodes. They develop more frequently in older adults and in immunocompromised individuals. B-cell lymphomas include both Hodgkins lymphomas and most non-Hodgkin lymphomas. They are typically divided into low and high grade, typically corresponding to indolent (slow-growing) lymphomas and aggressive lymphomas, respectively. As a generalisation, indolent lymphomas respond to treatment and are kept under control (in remission) with long-term survival of many years, but are not cured. Aggressive lymphomas usually require intensive treatments, with some having a good prospect for a permanent cure. Prognosis and treatment depends on the specific type of lymphoma as well as the stage and grade. Treatment includes radiation and chemotherapy. Early-stage indolent B-cell lymphomas can often be treated with radiation alone, with long-term non-recurrence. Early-stage aggressive disease is treated with ...
Cummings, R D.; Trowbridge, I S.; and Kornfeld, S, A mouse lymphoma cell line resistant to the leukoagglutinating lectin from phaseolus vulgaris is deficient in udp-glcnac:alpha- -d-mannoside beta1,6 n-acetylglucosaminyltransferase. (1982). Subject Strain Bibliography 1982. 1351 ...
What is Burkitt Lymphoma?. Burkitt lymphoma is a form of non-Hodgkins lymphoma which is a type of cancer that starts in the b-cells. Burkitt lymphoma is one of the fastest growing tumors. Burkitt lymphoma attacks the immune system and is fatal if not treated in a timely manner. There are three types of Burkitts lymphoma endemic, sporadic, and immunodeficiency- associated.. What causes Burkitt lymphoma? Who is affected?. The exact cause of Burkitt lymphoma is unknown, but there are factors associated with the disease such as Epstein-Barr. Individuals who are immunosuppressed have a higher risk factor for Burkitt lymphoma. Burkitt lymphoma primarily affects African children, and malaria may make children more vulnerable.. What are the symptoms of Burkitt lymphoma?. There are many symptoms associated with Burkitt lymphoma, including:. ...
Treatment for primary CNS lymphoma includes chemotherapy and often radiation therapy. Steroid therapy (e.g. dexamethasone) is often given before chemotherapy, as this helps reduce the swelling around the tumour, and may even shrink the tumour, reducing the raised intracranial pressure. Chemotherapy is given into a vein, and often also into the fluid surrounding the brain (intrathecally). Methotrexate is the drug most commonly given this way, and is also given in high doses intravenously- either on its own or in combination with other chemotherapy drugs and/or steroids. Radiotherapy uses high-energy rays to destroy the cancerous cells and can be an effective treatment for primary CNS lymphoma in younger people. It is used in combination with chemotherapy and steroid treatment. Surgery is only used to provide diagnostic tissue, and is never curative alone. Anticonvulsants may be given if seizures occur as a result of a tumour. If treatment is insufficient or if the disease recurs, some people are ...
The proportion of black or Hispanic patients with HIV-associated NHL increased from 41% in 2004 to 55% in 2012 (P < .0001). Chemotherapy was received by 81% of patients with diffuse large B-cell lymphoma, 90% of those with Burkitt lymphoma, 61% of those with primary effusion lymphoma (PEL), and 35% of those with primary central nervous system lymphomas (PCNSL). Between 2004 and 2012, this proportion increased only for patients with PCNSL (P < .00001). Chemotherapy was less likely to be received by patients who were older, black, or without private insurance. It was delivered more frequently in hospitals designated as academic (OR for nonreceipt, 0.68; 95% CI, 0.51-0.92) or in hospitals that had ≥3 HIV-positive cases per year (OR, 0.71; 95% CI, 0.58-0.86). Survival improved in patients with diffuse large B-cell lymphoma (P = .007), Burkitt lymphoma (P = .0002), and PCNSL (P = .019), but not in those with PEL (P = .94). Receipt of chemotherapy in patients with PEL was not associated with better ...
Lymphoma is the most common haematopoietic malignancy in dogs, and is the most responsive to chemotherapy. Affected dogs are typically middle-aged. Neither gender nor neutering is a predisposing factor for developing lymphoma. In studies of canine lymphoma epidemiology; boxers, Scottish terriers, German shepherds and poodles were more often affected, and recent evidence suggests a high incidence in golden retrievers. The most common physical finding in dogs with lymphoma is peripheral lymphadenopathy, which is usually generalized but may be localized to a single lymph node or a region of the body. Involvement of other organs, such as spleen, liver, or bone marrow is an indication of advanced disease. Involvement of other (extranodal) sites is rare in dogs. Untreated lymphoma progresses rapidly (1-2 months) from presentation to terminal stages. With chemotherapy, however, considerable improvement in the duration and quality of the patients life can be expected.. Staging and Diagnosis. Lymphoma ...
This study is to find the effectiveness of pembrolizumab in patients with relapsed and refractory gray-zone lymphoma (GZL), primary central nervous system
Double-hit lymphomas and double-expressor lymphomas are some of the most difficult non-Hodgkin lymphomas to treat. Patients with these types of lymphomas, which are subtypes of diffuse large B-cell lymphoma, dont respond as well to chemotherapy treatment as other lymphoma patients do.. An estimated 22,000 patients nationwide are diagnosed with diffuse large B-cell lymphoma each year. About 5 to 10 percent have double-hit lymphoma (or cancer cells that contain chromosomal rearrangements of the MYC, BCL2 and/or BCL6 genes) and about 20 to 30 percent have double-expressor lymphoma (containing the MYC and BCL2 genes).. Which is why Alex F. Herrera, M.D., an assistant professor in City of Hopes Department of Hematology and Hematopoietic Cell Transplantation, and a team of doctors at City of Hope and the Dana-Farber Cancer Institute examined how well patients whose double-hit and/or double-expressor lymphoma had recurred, or was resistant to initial treatment, fared after they had received high-dose ...
Clinical trial for Central Nervous System B-Cell Non-Hodgkin Lymphoma | CD20 Positive , Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete Response
Background Although chemo-immunotherapy has led to an improved overall survival for most B-cell lymphoma types, relapsed and refractory disease remains a challenge. The malaria drug artesunate has previously been identified as a growth suppressor in some cancer types and was tested as a new treatment option in B-cell lymphoma. Methods We included artesunate in a cancer sensitivity drug screen in B lymphoma cell lines. The preclinical properties of artesunate was tested as single agent in vitro in 18 B-cell lymphoma cell lines representing different histologies and in vivo in an aggressive B-cell lymphoma xenograft model, using NSG mice. Artesunate-treated B lymphoma cell lines were analyzed by functional assays, gene expression profiling, and protein expression to identify the mechanism of action. Results Drug screening identified artesunate as a highly potent anti-lymphoma drug.Artesunate induced potent growth suppression in most B lymphoma cells with an IC50 comparable to concentrations ...
This information is about non-Hodgkin lymphoma, a cancer that starts in the immune system. Non-Hodgkin lymphoma is also called NHL.. Non-Hodgkin lymphoma begins when a lymphocyte (usually a B cell) becomes abnormal. The abnormal cell divides to make copies of itself. The new cells divide again and again, making more and more abnormal cells. The abnormal cells dont die when they should. They dont protect the body from infections or other diseases. The buildup of extra cells often forms a mass of tissue called a growth or tumor.. Because lymphatic tissue is in many parts of the body, Hodgkin lymphoma can start almost anywhere. Usually, its first found in a lymph node.. When lymphoma is found, the pathologist reports the type. There are many types of lymphoma. The most common types are diffuse large B-cell lymphoma and follicular lymphoma.. Lymphomas may be grouped by how quickly they are likely to grow:. ...
Overview. Non-Hodgkins lymphoma is the seventh most common cancer in men and women in the United States. According to the American Cancer Society, 74000 new cases of non-Hodgkins lymphoma are diagnosed each year in the US. Non-Hodgkins lymphoma originates in the lymphatic system of the body. The lymphatic system fights diseases throughout the body. In non-Hodgkins lymphoma, tumors develop from white blood cells called lymphocytes. Lymph tissue is found in many places throughout the body, so lymphomas can start almost anywhere. Non-Hodgkins lymphoma is more common than the other type of general lymphoma, Hodgkin lymphoma. The major sites of lymph tissue are:. ...
Natural killer T (NKT) cells are a unique subset of CD1d-restricted T lymphocytes that express characteristics of both T cells and natural killer cells. NKT cells mediate tumor immune-surveillance; however, NKT cells are numerically reduced and functionally impaired in lymphoma patients. Many hematologic malignancies express CD1d molecules and co-stimulatory proteins needed to induce anti-tumor immunity by NKT cells, yet most tumors are poorly immunogenic. In this study, we sought to investigate NKT cell responses to B cell lymphoma. In the presence of exogenous antigen, both mouse and human NKT cell lines produce cytokines following stimulation by B cell lymphoma lines. NKT cell populations were examined ex vivo in mouse models of spontaneous B cell lymphoma, and it was found that during early stages, NKT cell responses were enhanced in lymphoma-bearing animals compared to disease-free animals. In contrast, in lymphoma-bearing animals with splenomegaly and lymphadenopathy, NKT cells were functionally
Non-Hodgkin lymphomas, which are defined as being all lymphomas except Hodgkin lymphoma, are more common than Hodgkin lymphoma ... Hodgkin lymphoma Classical Hodgkin lymphomas: Nodular sclerosis form of Hodgkin lymphoma Most common type of Hodgkin lymphoma ... large B-cell lymphoma ALK+ large B-cell lymphoma Plasmablastic lymphoma Primary effusion lymphoma Large B-cell lymphoma arising ... primary effusion lymphoma; plasmablastic lymphoma; extranodal NK/T cell lymphoma, nasal type; peripheral T cell lymphoma, not ...
... (MALToma) is a form of lymphoma involving the mucosa-associated lymphoid tissue (MALT), frequently of the stomach ... "MALT Lymphoma". The Lecturio Medical Concept Library. Retrieved 10 August 2021. "MALT Lymphoma". The Lecturio Medical Concept ... In contrast to small lymphocytic lymphoma and MCL, staining for CD5 is usually negative, and these lymphomas can be further ... Of all cancers involving the same class of blood cell, 8% of cases are MALT lymphomas. Primary cutaneous marginal zone lymphoma ...
FL may be confused with marginal zone B-cell lymphoma, mantle cell lymphoma, and the small lymphocytic lymphoma variant of ... plasmablastic lymphoma, the high grade subtype of B-cell lymphoma, Hodgkin lymphoma of the B-cell type, chronic lymphocytic ... plasmablastic lymphoma, the high grade subtype of B-cell lymphoma, Hodgkin lymphoma of the B-cell type, chronic lymphocytic ... Primary follicular lymphoma of the testis (PFLT), also termed testicular follicular lymphoma, was classified as a distinct form ...
... , also known as low-grade lymphoma, is a group of slow-growing non-Hodgkin lymphomas (NHLs). Because they ... Subtypes include follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, chronic lymphocytic leukemia, and ... Marginal zone lymphoma (MZL) is a heterogeneous group of indolent B cell lymphomas that arise from the marginal zone of ... Indolent lymphoma accounts for 41 percent of all non-Hodgkin lymphoma cases in North America and Northern Europe. It mainly ...
Cutaneous T-cell lymphoma Pleomorphic T-cell lymphoma Skin lesion Peripheral T-cell lymphoma-Not-Otherwise-Specified James, ... Lennert lymphoma is a systemic T-cell lymphoma that presents with cutaneous skin lesions roughly 10% of the time.: 739 It is ... Feller, AC.; Griesser, GH.; Mak, TW.; Lennert, K. (Sep 1986). "Lymphoepithelioid lymphoma (Lennert's lymphoma) is a monoclonal ... "Cutaneous involvement in the lymphoepithelioid variant of peripheral T-cell lymphoma, unspecified (Lennert lymphoma). Report of ...
Stage 1 Hodgkin lymphoma Stage 2 Hodgkin lymphoma Stage 3 Hodgkin lymphoma Stage 4 Hodgkin lymphoma Macroscopy Affected lymph ... Hodgkin lymphoma at Curlie Hodgkin Lymphoma at American Cancer Society Hodgkin Lymphoma at the American National Cancer ... The two major types of Hodgkin lymphoma are classic Hodgkin lymphoma and nodular lymphocyte-predominant Hodgkin lymphoma. About ... There are two main types of Hodgkin lymphoma: classic Hodgkin lymphoma and nodular lymphocyte predominant Hodgkin lymphoma. The ...
... is a rare cancer constituting 1% to 2% of all thyroid cancers and less than 2% of lymphomas. Thyroid lymphomas ... The majority of thyroid lymphomas are non-Hodgkin's B-cell lymphomas; a minority exhibit properties of T-cell lymphomas .[ ... Thus, Hashimoto's thyroiditis is considered a risk factor for thyroid lymphoma development. Thyroid lymphoma manifests as a ... large B-cell lymphoma with marginal zone Diffuse large B-cell lymphoma without marginal zone Marginal zone В-cell lymphoma of ...
... anaplastic lymphoma kinase-positive large B-cell lymphoma; and human herpesvirus 8-positive diffuse large B-cell lymphoma, not ... which they termed plasmablastic lymphoma, that had some features of a diffuse large B-cell lymphoma but unlike this lymphoma ... including diffuse B-cell lymphomas, chronic lymphocytic leukemia/small lymphocytic lymphoma, and follicular lymphoma generally ... Plasmablastic lymphoma (PBL) is a type of large B-cell lymphoma recognized by the World Health Organization (WHO) in 2017 as ...
These include AIDS-associated lymphoma, angioimmunoblastic lymphoma, Burkitt lymphoma, central nervous system (CNS) lymphoma, ... AIDS-associated lymphoma Angioimmunoblastic lymphoma Central nervous system (CNS) lymphoma Mantle cell lymphoma (MCL) Some of ... diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and peripheral T-cell lymphoma. Diffuse large B-cell lymphoma ... Aggressive lymphoma, also known as high-grade lymphoma, is a group of fast growing non-Hodgkin lymphoma. Some common symptoms ...
... is a rare malignant form of eye cancer. Intraocular lymphoma may affect the eye secondarily from a ... for B-cell lymphomas) or T-cell receptor (TCR, for the very rare T-cell lymphomas) can be performed. Previously, radiation ... Gonzales, John A.; Chan, Chi-Chao (August 2007). "Biopsy techniques and yields in diagnosing primary intraocular lymphoma". ... All articles with unsourced statements, Articles with unsourced statements from March 2021, Lymphoma, Ocular neoplasia, Epstein ...
... is a peer-reviewed medical journal published by Informa Healthcare. It covers basic and clinical aspects of ... "Leukemia & Lymphoma". 2014 Journal Citation Reports. Web of Science (Science ed.). Thomson Reuters. 2015.{{cite book}}: CS1 ... hematologic malignancies (leukemias and lymphomas). The editors-in-chief are Aaron Polliack (Hadassah University Hospital), ...
... of lymphoma cases can be attributed to Burkitt lymphoma. The peak incidence for endemic Burkitt lymphoma is from ages 4 to 7 ... Burkitt lymphoma is uncommon in adults, in whom it has a worse prognosis. Burkitt lymphoma can be divided into three main ... Since Burkitt lymphoma and other B-cell lymphomas are a clonal proliferative process, all tumor cells from one patient are ... As a non-Hodgkin lymphoma (NHL), Burkitt lymphoma makes up 1-5% of cases, and it is more common in males than females with a 3- ...
Other lymphomas involving the stomach include mantle cell lymphoma and T-cell lymphomas which may be associated with ... of all lymphomas. However, the stomach is a very common extranodal site for lymphomas (lymphomas originate elsewhere and ... Primary gastric lymphoma (lymphoma that originates in the stomach itself) is an uncommon condition, accounting for less than 15 ... An elevated LDH level may be suggestive of lymphoma. Diffuse large B-cell lymphomas of the stomach are primarily treated with ...
... , also known as lymphoma cutis, is when lymphoma involves the skin. It is characterized by a proliferation of ... There are two main classes of lymphomas that affect the skin:[citation needed] Cutaneous T-cell lymphoma Cutaneous B-cell ... lymphoma Paller, Amy S.; Mancini, Anthony J. (2015). Hurwitz Clinical Pediatric Dermatology: A Textbook of Skin Disorders of ...
... intraocular lymphomas and adnexal lymphomas. An intraocular lymphoma occurs within the eye, while an adnexal lymphoma occurs ... Follicular lymphoma, diffuse large B cell lymphoma, mantle cell lymphoma, B-cell chronic lymphocytic leukemia, peripheral T- ... Orbital lymphoma is a common type of non-Hodgkin lymphoma that occurs near or on the eye. Common symptoms include decreased ... Orbital lymphoma is more prevalent in Asia and Europe than in the United States. Although intraocular lymphoma is rare, the ...
"07:36 Lymphoma Association: 2008 winners announced". Live Care News. Lymphoma Association v t e (Use dmy dates from April 2022 ... Founded by patients in 1986, the Lymphoma Association is a charitable organisation based in the United Kingdom that offers ...
The Leukemia & Lymphoma Society, Our History The Leukemia & Lymphoma Society, History Beat AML "The Leukemia & Lymphoma Society ... About The Leukemia & Lymphoma Society "The Leukemia & Lymphoma Society Offers Research, Advocacy and Patient Support". Cure ... The LLS's mission is to cure leukemia, lymphoma, Hodgkin's lymphoma and myeloma, and improve the quality of life of patients ... "Our history". Leukemia & Lymphoma Society. Retrieved 8 October 2018. "Executive leadership team". The Leukemia & Lymphoma ...
... (PEL) is classified as a diffuse large B cell lymphoma. It is a rare malignancy of plasmablastic ... Shin J, Lee JO, Choe JY, Bang SM, Lee JS (January 2017). "Human Herpesvirus 8-Unrelated Primary Effusion Lymphoma-Like Lymphoma ... 2016 as a KSHV/HHV8-positive and KSHV/HHV8-driven large B-cell lymphoma. This lymphoma also belongs to a group of lymphoid ... Human herpes virus 8-negative primary effusion lymphoma-like lymphoma recurring as a tumor adjacent to the left atrium]". [ ...
In MeSH, the phrase "mixed-cell lymphoma" is currently classified under non-Hodgkin lymphoma. Mixed+cell+lymphoma at the US ... Mixed-cell lymphomas are lymphomas that have both large cells and small cells in them.[citation needed] This nomenclature is ...
The B-cell lymphomas are types of lymphoma affecting B cells. Lymphomas are "blood cancers" in the lymph nodes. They develop ... B-cell lymphomas include both Hodgkin's lymphomas and most non-Hodgkin lymphomas. They are typically divided into low and high ... granulomatosis Primary central nervous system lymphoma ALK+ large B-cell lymphoma Plasmablastic lymphoma Large B-cell lymphoma ... diffuse large B-cell lymphoma Primary testicular diffuse large B-cell lymphoma Burkitt's lymphoma Lymphoplasmacytic lymphoma, ...
... (ALK) was originally discovered in 1994 in anaplastic large-cell lymphoma (ALCL) cells. ALCL is ... November 2008). "The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 ... February 2004). "Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c ... February 2014). "Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients". Journal of the ...
The workup for mantle cell lymphoma is similar to the workup for many indolent lymphomas and certain aggressive lymphomas. ... Mantle cell lymphoma (MCL) is a type of non-Hodgkin's lymphoma (NHL), comprising about 6% of NHL cases. There are only about ... Leukemia&Lymphoma Society (2014). "Mantle Cell Lymphoma Facts" (PDF). www.LLS.org. Tatsuno K, Fujiyama T, Matsuoka H, Shimauchi ... The normal range is approximately 100-190.[medical citation needed] 6% of non-Hodgkin lymphoma cases are mantle cell lymphoma. ...
Am J Surg Pathol 2005 Nov; 29(11):1411-21 Hodgkin's lymphoma and Grey-zone lymphomas v t e (Lymphoma, All stub articles, ... Gray zone lymphoma, often presenting as large tumors in the mediastinum, is a type of lymphoma that is characterized by having ... Traverse-Glehen A, Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B- ... cellular features of both classic Hodgkin's lymphomas (cHL) and large B-cell lymphomas. ...
Other groups of lymphomas in this system are the small-cell lymphomas and mixed-cell lymphomas. Diffuse large B-cell lymphoma ... lymphoma Burkitt's lymphoma Follicular large-cell lymphoma Immunoblastic lymphoma Intravascular large-cell lymphoma Primary ... Anaplastic large-cell lymphoma is an example of a large-cell lymphoma that involves T cells. Of the large-cell T-cell lymphomas ... MeSH now classifies the phrase "large-cell lymphoma" under "Diffuse large B cell lymphoma". Many other B-cell lymphomas feature ...
If the lymphoma is located in the nose, the cat may have discharge from the nose and facial swelling. Lymphoma of the heart ... Lymphoma of the kidney is the most common kidney tumor in cats, and lymphoma is also the most common heart tumor. ... If lymphoma develops in the kidney, the cat may have increased water consumption and increased urination. Lymphoma of the ... Lymphoma in the mediastinum, spleen, skin, and peripheral lymph nodes has the best prognosis, while lymphoma in the intestine, ...
B-cell lymphoma Non-Hodgkin lymphoma Hodgkin lymphoma Lymphoma Quesenberry, Peter J.; Castillo, Jorge J. (2013). Non-Hodgkin ... T-cell lymphoma is a rare form of cancerous lymphoma affecting T-cells. Lymphoma arises mainly from the uncontrolled ... angioimmunoblastic T-cell lymphoma (AITL), extranodal NK/T-cell lymphoma, nasal type, and Peripheral T-cell lymphoma not ... Angioimmunoblastic T-cell lymphoma (AITL): Aggressive form of T-cell lymphoma.[citation needed] Anaplastic large cell lymphoma ...
Hepatitis C virus: associated with splenic marginal zone lymphoma, lymphoplasmacytic lymphoma and diffuse large B-cell lymphoma ... also known as non-Hodgkin's lymphoma, is a group of blood cancers that includes all types of lymphomas except Hodgkin lymphomas ... Lymphomas in the skin may also result in lumps, which are commonly itchy, red, or purple. Lymphomas in the brain can cause ... To this day, lymphoma statistics are compiled as Hodgkin's versus non-Hodgkin lymphomas by major cancer agencies, including the ...
B-cell immunoblastic lymphoma, and Burkitt's lymphoma (small non-cleaved cell lymphoma). The symptoms of AIDS-related lymphoma ... AIDS-related lymphoma describes lymphomas occurring in patients with acquired immunodeficiency syndrome (AIDS). A lymphoma is a ... Primary cerebral lymphoma (or primary central nervous system lymphoma) is a form of NHL. It is very rare in immunocompetent ... In AIDS, the incidences[spelling?] of non-Hodgkin's lymphoma, primary cerebral lymphoma and Hodgkin's disease are all increased ...
"Lymphoma Action , Biopsy". Lymphoma Action. Retrieved 2020-04-08. "Lymphoma Action , Blood tests". Lymphoma Action. Retrieved ... Mature T-cell lymphoma is under the category of non-Hodgkin lymphoma. Mature T-cell lymphomas account for 10% to 15% of all ... Mature T-cell lymphoma, also called peripheral T-cell lymphoma, is a group of rare, aggressive lymphomas that develop from ... "Lymphoma Action , Tests, diagnosis and staging". Lymphoma Action. Retrieved 2020-04-26. "Peripheral T-Cell Lymphoma: Treatment ...
... leg type Primary cutaneous follicular lymphoma Primary cutaneous marginal zone lymphoma Intravascular large B-cell lymphoma ... Cutaneous B-cell lymphomas constitute a group of diseases that occur less commonly than cutaneous T-cell lymphoma, and are ... Plasmacytoma Plasmacytosis Cutaneous T-cell lymphoma List of cutaneous conditions James, William D.; Berger, Timothy G.; et al ... 740-743 Primary cutaneous diffuse large B-cell lymphoma, ... Lymphoma, All stub articles, Cutaneous condition stubs). ...
Lymphoma is a general term for cancers that start in the lymph system (the tissues and organs that produce, store, and carry ... Symptoms of Lymphoma. Symptoms of Hodgkin lymphoma and non-Hodgkin lymphoma include swollen lymph nodes, especially in the part ... What Causes Lymphoma?. Non-Hodgkin lymphoma becomes more common as people get older. Unlike most cancers, rates of Hodgkin ... See how the rates of new non-Hodgkin lymphomas or non-Hodgkin lymphoma deaths changed over time for the entire United States ...
Lymphoma. Lymphoma, Mantle-Cell. Neoplasms by Histologic Type. Neoplasms. Lymphoproliferative Disorders. Lymphatic Diseases. ... ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM) (AIM). The safety and scientific validity of this study is the responsibility ... Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma. N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/ ... Subject must have a confirmed diagnosis of Mantle Cell Lymphoma (MCL) according to WHO (2008) criteria, and have received at ...
... is a potentially curable lymphoma with distinct histology, biologic behavior, and clinical characteristics. The disease is ... Non-Hodgkin lymphoma, particularly diffuse large B cell lymphoma and anaplastic large cell lymphoma, both of which may have ... Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology ... Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may ...
... non-Hodgkin lymphoma (NHL) is the most common type of ocular lymphoma. Depending on the site of involvement, ocular lymphoma ... Whereas Hodgkin lymphoma very rarely causes ocular disease, ... Pediatric Non-Hodgkin Lymphoma * Thoracic Non-Hodgkin Lymphoma ... Whereas Hodgkin lymphoma rarely causes ocular disease, non-Hodgkin lymphoma (NHL) is the most common type of ocular lymphoma. ... Orbital and adnexal lymphoma is associated with systemic lymphoma in 30-35% of cases. Hence, all patients with ocular lymphoma ...
... is a very fast growing form of non-Hodgkin lymphoma. ... B-cell lymphoma; High-grade B-cell lymphoma; Small noncleaved ... Adult non-Hodgkin lymphoma treatment (PDQ) - health professional version. www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment- ... Burkitt lymphoma (BL) is a very fast growing form of non-Hodgkin lymphoma. ...
Update on Mantle Cell Lymphoma for Caregivers. *Caring for Your Loved One with Mantle Cell Lymphoma, in the Context of COVID-19 ... Coping with the Stresses of Caregiving When Your Loved One Has Mantle Cell Lymphoma (MCL). Part II of Living with Mantle Cell ... Mantle Cell Lymphoma: Treatment Update. *Adjusting to Your Blood Cancer Treatment Over Time: Challenges and Opportunities of ...
Among relapsed or refractory patients with mantle cell lymphoma, lenalidomide showed rapid and durable efficacy. ... "Phase 2 trials have shown activity across the board in lymphomas with lenalidomide, but especially in mantle cell lymphoma," ... has shown promise in the treatment of mantle cell lymphoma (MCL), one of the rarest non-Hodgkins lymphomas. ... Activity in Lymphoma Lenalidomide has demonstrated tumoricidal and antiproliferative effects in MCL and clinical activity and ...
JavaScript is disabled for your browser. Some features of this site may not work without it ...
In general, lymphomas are divided into 2 large groups of neoplasms, namely non-Hodgkin lymphoma (NHL) and Hodgkin disease. ... The term lymphoma describes a heterogeneous group of malignancies with different biology and prognosis. ... Primary CNS lymphoma in children and adolescents: a descriptive analysis from the international primary CNS lymphoma ... Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the ...
The Past, Present, and Future of Bendamustine in Mantle Cell Lymphoma * How Medicare Could Save $1.29 Billion a Year on Urology ... At the time of its US approval, Ian Flinn, MD, PhD, director of the Lymphoma Research Program at Sarah Cannon Research ... More recently, promising results for duvelisib for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) suggest ... Cite this: EU Panel Endorses Duvelisib for CLL and Follicular Lymphoma - Medscape - Mar 29, 2021. ...
C86.3 - Subcutaneous panniculitis-like T-cell lymphoma. SNOMEDCT:. 404133000 - Subcutaneous panniculitis-like T-cell lymphoma. ... Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare cutaneous T-cell lymphoma that mimics panniculitis clinically ... Primary cutaneous γ/δ T-cell lymphoma - A more aggressive cutaneous lymphoma with similar clinical presentation to SPTCL, with ... Subcutaneous panniculitis-like T-cell lymphoma. Subscriber Sign In Feedback Select Language ...
Primary cerebral lymphoma[edit]. Primary cerebral lymphoma (or primary central nervous system lymphoma) is a form of NHL. It is ... Diffuse large B-cell lymphoma, B-cell immunoblastic lymphoma, and Burkitts lymphoma (small non-cleaved cell lymphoma).[3] ... A lymphoma is a type of cancer arising from lymphoid cells. In AIDS, the incidences[spelling?] of non-Hodgkins lymphoma, ... Non-Hodgkins lymphoma[edit]. Non-Hodgkins lymphoma (NHL) is present in about 1%-3% of HIV seropositive people at the time of ...
Meeting about the results from his trial of MOR208 plus lenalidomide in relapsed/refractory diffuse large B-cell lymphoma.. ...
Follicular lymphoma of mixed cell types also occurs.. *Mantle cell lymphoma is an aggressive lymphoma of small B-cells derived ... Lymphoblastic lymphoma is a high-grade lymphoma, is composed of precursor T or B lymphoid cells, and can occur in all age ... Peripheral T-cell lymphomas occur more frequently in adults and are much less common than B cell lymphomas in the United States ... A follicular lymphoma composed mainly of small-cleaved cells is a low-grade lymphoma and the leukemic form has been referred to ...
Her Battle Against Hodgkins Lymphoma. "Now when you die, your life goes on.. It doesnt end here when youre gone. "And now ... This was when we found out that the diagnosis was definitely Hodgkins Lymphoma. Her diagnosis was Hodgkins Lymphoma nodular ... The surgeons said that from her symptoms, it appeared that she was suffering from some type of lymphoma. Lab results of the ... In late September of 2002, Melissa Leigh Sutton, age 24, was diagnosed with Hodgkins Lymphoma. She had been sick, on and off, ...
Mathé, Georges; Rappaport, Henry; OConor, G. T; Torloni, Humberto; World Health Organization (‎Organisation mondiale de la Santé, 1976)‎ ...
... and appropriate follow-up for safe and accurate diagnosis of lymphoma. ... follicular lymphoma; HL, Hodgkin lymphoma, MCL, mantle cell lymphoma; NK, natural killer; SLL, small lymphocytic lymphoma.. a ... Table 5. Secondary Reviews for Different Lymphomas Highly Reproducible Lymphoma Typesa Lymphoma Types for Which Secondary ... Note: For certain lymphoma types (eg, splenic low-grade lymphomas, lymphoplasmacytic lymphomas) bone marrow biopsy may be ...
Lymphomas are cancers of lymphocytes. Leukemia is cancer of the blood. It does not usually form solid tumors. Sarcomas arise in ... The major types of cancer are carcinoma, sarcoma, melanoma, lymphoma, and leukemia. Carcinomas -- the most commonly diagnosed ...
... Guest edited by: Dr Sam Mbulaiteye. Burkitt Lymphoma (BL) is an aggressive non-Hodgkin ... Burkitt Lymphoma: beyond discoveries First described in 1958 in Uganda, Burkitt lymphoma (BL) attracted interest worldwide ... Particularly, Burkitts lymphoma belongs to the family of B Non Hodgkin aggressive lymphomas. Although it is morph... ... Identification of a novel variant of LMP-1 of EBV in patients with endemic Burkitt lymphoma in western Kenya Epstein Barr virus ...
The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against cancer. The LLS mission: Cure leukemia, lymphoma ... The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest ...
Peripheral T-cell lymphoma is a rare and aggressive type of cancer that affects mature T cells. Learn more about the treatments ... The Epstein-Barr virus causes lymphomas, including Burkitt lymphoma and diffuse large B-cell lymphoma. A 2021 in-vitro study ... Lymphoma is a cancer that starts in the white blood cells This article looks at the two main types: Hodgkin lymphoma and non- ... Peripheral T-cell lymphomas (PTCLs) are rare, aggressive lymphomas that affect mature T cells. "Peripheral" means the cancer ...
Care guide for Non-Hodgkin Lymphoma (Ambulatory Care). Includes: possible causes, signs and symptoms, standard treatment ... Non-Hodgkin lymphoma causes lymphocytes to grow and divide without control and to form tumors. Non-Hodgkin lymphoma can develop ... More About Non-Hodgkin Lymphoma (Ambulatory Care) Medication Guide 1 related article ... Non-Hodgkin lymphoma,. or non-Hodgkin disease, is a cancer of the lymphatic system. The lymphatic system contains lymph vessels ...
Lymphoplasmacytic lymphoma (LPL) is a rare type of cancer. Well tell you the symptoms, causes, treatment options, and what to ... Lymphomas are broadly categorized as non-Hodgkins lymphomas or Hodgkins lymphomas. Hodgkins lymphomas have a specific kind ... LPL is a non-Hodgkins lymphoma. Its a very rare lymphoma, making up only about 1%-2%. of all lymphomas. ... cancer.ca/en/cancer-information/cancer-types/non-hodgkin-lymphoma/what-is-non-hodgkin-lymphoma/lymphoplasmacytic-lymphoma. ...
This was a carefully done study which clearly demonstrated a statistically significant increase in several types of lymphomas ... Morando Soffritti found aspartame to be a multipotential carcinogen causing everything from leukemia and lymphoma to lung, ... means that drinking a single diet cola sweetened with aspartame every day could increase ones risk of developing a lymphoma or ...
Foundation collaborated on work that resulted in patent filings for the drug bexarotene to treat cutaneous T-cell lymphoma-a ... approved in 1999 by the Food and Drug Administration to treat cutaneous T-cell lymphoma-a rare disorder of the immune system ...
The Lymphoma Research Foundations mission is to eradicate lymphoma and serve those impacted by this blood cancer. ... Telehealth can be a valuable support to standard of care practices for patients with lymphoma. It provides a flexible platform ... confirm the patients diagnosis and evaluate if the course of treatment is the most appropriate based on the type of lymphoma. ...
Wine golf event on June 1 will benefit the Leukemia and Lymphoma Society. The afternoon starts with golf and ends with music ... Golf Party Will Benefit Leukemia & Lymphoma Society. May 24, 2012 / 4:34 PM. / CBS Detroit ... The Team LaFontaine 9 &Wine golf event on June 1 will benefit the Leukemia and Lymphoma Society. The afternoon starts with golf ...
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course is variable, ... 3 International Extranodal Lymphoma Study Group, Bellinzona, Switzerland.. *4 Lymphoma Genomics, Institute of Oncology Research ... Genetic and phenotypic attributes of splenic marginal zone lymphoma Blood. 2022 Feb 3;139(5):732-747. doi: 10.1182/blood. ... Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course is variable, ...
... and Gabriela Galicia Vazquez will study a eukaryotic initiation factor as a molecular target for lymphoma treatment. ... to researchers at the University of Montreal and McGill University to fund a range of studies focused on leukemia and lymphoma ...
  • Hodgkin lymphoma, which spreads in an orderly manner from one group of lymph nodes to another. (cdc.gov)
  • Non-Hodgkin lymphoma, which spreads through the lymphatic system in a non-orderly manner. (cdc.gov)
  • Hodgkin lymphoma and non-Hodgkin lymphoma can occur in children, teens, and adults. (cdc.gov)
  • Non-Hodgkin lymphoma becomes more common as people get older. (cdc.gov)
  • Unlike most cancers, rates of Hodgkin lymphoma are highest among teens and young adults (ages 15 to 39 years) and again among older adults (ages 75 years or older). (cdc.gov)
  • White people are more likely than Black people to develop non-Hodgkin lymphoma, and men are more likely than women to develop lymphoma. (cdc.gov)
  • People exposed to high levels of ionizing radiation have a higher risk of developing non-Hodgkin lymphoma. (cdc.gov)
  • Family history has been linked with a higher risk of Hodgkin lymphoma. (cdc.gov)
  • Symptoms of Hodgkin lymphoma and non-Hodgkin lymphoma include swollen lymph nodes, especially in the part of the body where the lymphoma starts to grow. (cdc.gov)
  • See rates or numbers of new Hodgkin lymphomas or Hodgkin lymphoma deaths for the entire United States and individual states. (cdc.gov)
  • See rates or numbers of new Hodgkin lymphomas or Hodgkin lymphoma deaths by race/ethnicity, sex, and age group. (cdc.gov)
  • See rates or numbers of new non-Hodgkin lymphomas or non-Hodgkin lymphoma deaths for the entire United States and individual states. (cdc.gov)
  • Occasionally, Hodgkin lymphoma can present as hemophagocytic syndrome ( hemophagocytic lymphohistiocytosis ). (medscape.com)
  • Guideline] NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma. (medscape.com)
  • Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (medscape.com)
  • Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. (medscape.com)
  • Whereas Hodgkin lymphoma rarely causes ocular disease, non-Hodgkin lymphoma (NHL) is the most common type of ocular lymphoma. (medscape.com)
  • Burkitt lymphoma (BL) is a very fast growing form of non-Hodgkin lymphoma . (medlineplus.gov)
  • Adult non-Hodgkin lymphoma treatment (PDQ) - health professional version. (medlineplus.gov)
  • Thus, the diagnosis of non-Hodgkin lymphoma (NHL) relies on pathological confirmation following appropriate tissue biopsy. (medscape.com)
  • Hodgkin lymphoma with cutaneous involvement. (medscape.com)
  • Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. (medscape.com)
  • Cancer Stat Facts: Non-Hodgkin Lymphoma. (medscape.com)
  • Time trends in risk and risk determinants of non-hodgkin lymphoma in solid organ transplant recipients. (medscape.com)
  • Burkitt Lymphoma (BL) is an aggressive non-Hodgkin lymphoma (NHL) that was first described by Dennis Burkitt in 1958 in Ugandan children. (biomedcentral.com)
  • This cancer is a subtype of non-Hodgkin lymphoma (NHL) and accounts for 6-10% of all NHL cases. (medicalnewstoday.com)
  • Non-Hodgkin lymphoma causes lymphocytes to grow and divide without control and to form tumors. (drugs.com)
  • Non-Hodgkin lymphoma can develop in any lymph tissue in the body. (drugs.com)
  • Some types of non-Hodgkin lymphoma grow and spread slowly and are called indolent. (drugs.com)
  • There may be a genetic component, as about 20% of people with WM have a first-degree relative with LPL or a similar non-Hodgkin lymphoma (NHL). (healthline.com)
  • People recovering from Hodgkin lymphoma are encouraged to follow established guidelines for good health, such as not smoking, limiting alcohol, eating well, exercising regularly, and managing stress. (cancer.net)
  • R-CHOP is widely used in non-Hodgkin lymphoma. (verywellhealth.com)
  • When facing a non-Hodgkin lymphoma diagnosis, the data matters. (moffitt.org)
  • Primary thyroid Hodgkin lymphoma is extremely rare. (medscape.com)
  • Researchers seek to improve success of chimeric antigen receptor-T cell therapy in non-Hodgkin lymphoma May 12, 2022, 07:04 p.m. (mayoclinic.org)
  • A number of treatments are used for non-Hodgkin lymphoma (NHL). (childrensoncologygroup.org)
  • Chemotherapy is the standard treatment for non-Hodgkin lymphoma. (childrensoncologygroup.org)
  • Researchers currently DO NOT know what causes non-Hodgkin lymphoma and only a few risk factors for non-Hodgkin lymphoma are known for sure. (childrensoncologygroup.org)
  • Boys are two to three times more likely to develop non-Hodgkin lymphoma before age 20 compared to girls. (childrensoncologygroup.org)
  • Caucasian children are about 40% more likely to develop non-Hodgkin lymphoma compared to African American children. (childrensoncologygroup.org)
  • Children with impaired immune system are more likely to develop non-Hodgkin lymphoma than other children. (childrensoncologygroup.org)
  • Children with these conditions are more at risk for non-Hodgkin lymphoma, but they account for only a small fraction of cases. (childrensoncologygroup.org)
  • Researchers are studying the causes of non-Hodgkin lymphoma. (childrensoncologygroup.org)
  • Researchers investigating the causes of non-Hodgkin lymphoma usually will interview one or both parents by telephone. (childrensoncologygroup.org)
  • The International Prognostic Index (IPI), which was originally designed as a prognostic factor model for aggressive non-Hodgkin lymphoma (NHL), also appears to be useful for predicting the outcome of patients with low-grade lymphoma. (medscape.com)
  • There are several types of lymphoma, with a primary distinction being made between Hodgkin lymphoma and non-Hodgkin lymphoma, or NHL, explains Healthline. (reference.com)
  • This initial distinction means that stage IV Hodgkin lymphoma and stage IV NHL describe different conditions, and therefore may involve different prognoses. (reference.com)
  • Many of the symptoms for both NHL and Hodgkin lymphoma are similar, including weight loss, fevers, increasing fatigue, itching and night sweats, according to Healthline. (reference.com)
  • Treatments for both NHL and Hodgkin lymphoma involve various chemotherapy regimens, and a stem cell transplant may be considered for Hodgkin lymphoma that doesn't respond to chemotherapy. (reference.com)
  • To explore the possible relationship between non-Hodgkin lymphoma (NHL) and carbamate insecticide use among farmers, a pooled analysis of three population-based case-control studies conducted in four mid-western states in the United States was conducted involving 985 white male subjects and 2895 matched controls. (ilo.org)
  • The U.S. Food and Drug Administration (FDA) recently approved a new immunotherapeutic called mogamulizumab-kpkc (Poteligeo) for treating certain patients with two rare types of non-Hodgkin lymphoma , mycosis fungoides and Sézary syndrome. (aacr.org)
  • Mycosis fungoides and Sézary syndrome are types of non-Hodgkin lymphoma that arise in immune cells called T cells. (aacr.org)
  • Childhood non-Hodgkin lymphoma treatment can include chemotherapy, radiation therapy, targeted therapy, and high-dose chemotherapy with stem cell transplant. (oncolink.org)
  • Childhood non-Hodgkin lymphoma is a disease in which malignant (cancer) cells form in the lymph system, which is a part of the body's immune system. (oncolink.org)
  • There are three major types of childhood non-Hodgkin lymphoma. (oncolink.org)
  • Some types of non-Hodgkin lymphoma are rare in children. (oncolink.org)
  • Signs of childhood non-Hodgkin lymphoma include breathing problems and swollen lymph nodes. (oncolink.org)
  • Tests that examine the body and lymph system are used to diagnose childhood non-Hodgkin lymphoma. (oncolink.org)
  • A biopsy is done to diagnose childhood non-Hodgkin lymphoma. (oncolink.org)
  • Most types of non-Hodgkin lymphoma begin in B lymphocytes. (oncolink.org)
  • Non-Hodgkin lymphoma can begin in B lymphocytes, T lymphocytes, or natural killer cells. (oncolink.org)
  • This summary is about the treatment of childhood non-Hodgkin lymphoma. (oncolink.org)
  • For information about the treatment of childhood Hodgkin lymphoma, see Childhood Hodgkin Lymphoma Treatment. (oncolink.org)
  • Treatment of non-Hodgkin lymphoma is different for children and adults. (oncolink.org)
  • Major related diseases include kidney and bladder cancers, non-Hodgkin lymphoma (NHL) and cardiac defects. (mesothelioma.com)
  • He reports that 2 unrelated friends have been diagnosed with Hodgkin lymphoma in the past 5 years, prompting his concern. (mhmedical.com)
  • Hodgkin lymphoma is a distinct type of lymphoma that in many ways offers a paradigm for the diagnosis and treatment of all hematologic malignancies. (mhmedical.com)
  • Although the causes of Hodgkin lymphoma still remain largely unknown, advances in chemo- and radiotherapy have converted this previously lethal disease to one that is highly curable. (mhmedical.com)
  • Before these treatment regimens were available, 90% of patients with Hodgkin lymphoma died within 2-5 years, whereas 85%-90% are now curable with modern therapy. (mhmedical.com)
  • Therefore, Hodgkin lymphoma is one of the best examples of a strategic approach to malignancy leading to cure. (mhmedical.com)
  • Now that most patients with Hodgkin lymphoma can be cured, the long-term toxicity of the treatments has come into sharp focus, especially long-term vascular/cardiotoxicity and the development of secondary malignancies. (mhmedical.com)
  • The incidence of Hodgkin lymphoma (HL) has been linked to several factors, including environmental, social status, infectious agents, and genetic propensity. (mhmedical.com)
  • Hodgkin lymphoma is a potentially curable lymphoma. (medscape.com)
  • Mixed cellularity Hodgkin lymphoma showing both mononucleate and binucleate Reed-Sternberg cells in a background of inflammatory cells (hematoxylin and eosin, original magnification x200). (medscape.com)
  • A histologic diagnosis of Hodgkin lymphoma is always required. (medscape.com)
  • See also the Medscape article Hodgkin Lymphoma Staging . (medscape.com)
  • [ 6 ] provide consensus opinions from leading experts on evidence-based approaches to the diagnosis and treatment of Hodgkin lymphoma. (medscape.com)
  • The purpose of this study is to assess the safety and effectiveness of combining pembrolizumab immunotherapy with standard chemotherapy drugs and autologous stem cell transplantation (ASCT) in patients with Hodgkin lymphoma that has come back or continued to grow despite one regimen of prior therapy. (mskcc.org)
  • Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 289, "Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma: Preliminary Safet. (ascopost.com)
  • There is strong evidence that the use of pesticides increases the risk of hematological malignancies, but associations with Hodgkin lymphoma remain poorly understood. (who.int)
  • Among a total of 316,270 farmers (75% male), 91 incident Hodgkin lymphoma cases were diagnosed during follow-up from 1993 to 2011 (3,574,815 person-years). (who.int)
  • Hodgkin lymphoma, which the working group stated was unlikely due to chance although confounding could not be excluded. (who.int)
  • Follicular lymphoma international prognostic index. (medscape.com)
  • European Union approval has been recommended for duvelisib (Copiktra) for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or refractory follicular lymphoma (FL) who have received at least two prior lines of therapy. (medscape.com)
  • Follicular lymphoma is a relatively common B-cell lymphoma composed of varying numbers of small-cleaved and large cells from follicle centers and occurs mainly in adults. (wisc.edu)
  • A follicular lymphoma composed mainly of small-cleaved cells is a low-grade lymphoma and the leukemic form has been referred to as lymphosarcoma. (wisc.edu)
  • Follicular lymphoma composed mainly of large cells is of intermediate grade. (wisc.edu)
  • Follicular lymphoma of mixed cell types also occurs. (wisc.edu)
  • R-CHOP may also be used in certain cases of follicular lymphoma , according to the 2017 Guidelines from the National Comprehensive Cancer Network. (verywellhealth.com)
  • In 2001, the WHO classification called for grading of follicular lymphoma (FL) from grades 1-3 based on the number of centroblasts per high-power field (hpf). (medscape.com)
  • The Food and Drug Administration approved lenalidomide (REVLIMID®, Celgene Corp.) in combination with a rituximab product for previously treated follicular lymphoma (FL) and previously treated marginal zone lymphoma (MZL). (hematology.org)
  • Diffuse large B-cell lymphoma , B-cell immunoblastic lymphoma, and Burkitt's lymphoma (small non-cleaved cell lymphoma). (wikipedia.org)
  • Burkitt's lymphoma is a high-grade B-cell lymphoma occurring more frequently in the young. (wisc.edu)
  • Burkitt's lymphoma can occur in adults and may be associated with immunodeficiency. (wisc.edu)
  • Particularly, Burkitt's lymphoma belongs to the family of B Non Hodgkin aggressive lymphomas. (biomedcentral.com)
  • Burkitt lymphoma (Burkitt's tumor, Burkitt's lymphoma, or malignant lymphoma, Burkitt's type) is a cancer of the lymphatic system, particularly B lymphocytes found in the germinal center. (icd.codes)
  • IMSEAR at SEARO: Burkitt's lymphoma. (who.int)
  • Burkitt's lymphoma is one of the fastest growing malignancies in the pediatric population. (bvsalud.org)
  • The African, or endemic, variant usually involves the maxilla and other facial bones, while head and neck manifestations in sporadic Burkitt's lymphoma are rare. (bvsalud.org)
  • Two cases of oral manifestations of Burkitt's lymphoma are described on the right jaw in young patients, which had different clinical evolution and prognosis. (bvsalud.org)
  • EBV, infectious mononucleosis (IM), glandular fever, Burkitt's lymphoma (BL), nasopharyngeal carcinoma (NPC) Footnote 1 Footnote 2 . (canada.ca)
  • Burkitt's lymphoma may be endemic, sporadic or im munodeficiency associated Footnote 3 . (canada.ca)
  • Burkitt's lymphoma arises due to an early infection with EBV virus resulting in infected B cells Footnote 4 Footnote 8 . (canada.ca)
  • Endemic Burkitt's lymphoma frequently affects the facial bones, particularly the jaw, maxilla, and orbit, in young children Footnote 8 . (canada.ca)
  • The sporadic Burkitt's lymphoma arises in the lymphoid tissues of the gut and the upper respiratory tract Footnote 8 . (canada.ca)
  • Endemic Burkitt's lymphoma occurs frequently in young children in the equatorial regions of Africa and Papua New Guinea and has an incidence of 50-100 cases per 1,000,000 individuals Footnote 7 . (canada.ca)
  • Endemic Burkitt's lymphoma is almost 100% associated with EBV, whereas, association of sporadic Burkitt's lymphoma with EBV is low (15-30% of cases) Footnote 7 . (canada.ca)
  • Dr Johannes Düll speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about the results from his trial of MOR208 plus lenalidomide in relapsed/refractory diffuse large B-cell lymphoma. (ecancer.org)
  • Diffuse large B-cell lymphoma is an intermediate grade lymphoma which occurs in all age groups and more frequently in older adults. (wisc.edu)
  • The Epstein-Barr virus causes lymphomas, including Burkitt lymphoma and diffuse large B-cell lymphoma. (medicalnewstoday.com)
  • R-CHOP is considered a standard treatment for one of the most common types of NHL, diffuse large B-cell lymphoma (​DLBCL). (verywellhealth.com)
  • The most common subtype of NHLs that arise primarily from the thyroid gland is diffuse large-cell lymphoma (DLBCL). (medscape.com)
  • CNS relapse in the brain parenchyma, eyes, or leptomeninges is an uncommon but devastating complication of diffuse large B-cell lymphoma. (thelancet.com)
  • National Comprehensive Cancer Network (NCCN) guidelines note that that grade 3B is commonly treated as diffuse large B-cell lymphoma (DLBCL), whereas opinion is divided on whether to treat grade 3A as FL or DLBCL. (medscape.com)
  • Primary cutaneous diffuse large B-cell lymphoma, leg type. (bccancer.bc.ca)
  • A recent study in The Lancet Oncology demonstrated that liquid biopsy in diffuse large B-cell lymphoma (DLBCL) could identify a recurrence at 3.5 months before CT scan on average. (medpagetoday.com)
  • Mark Roschewski, MD, of the National Cancer Institute, and colleagues agreed, writing that in patients with diffuse large B-cell lymphoma (DLBCL), for example, "the effectiveness of therapy is often based on post-treatment imaging scans, which are limited by an inability to detect disease at the molecular level and frequent false-positive results. (medpagetoday.com)
  • Chimeric antigen receptor T-cell (CAR-T) therapy and antibody conjugates may be important treatment advances for people diagnosed with diffuse large B-cell lymphoma and other cancers. (formularywatch.com)
  • Vijenthira and her colleagues constructed a Markov model to compare four treatment strategies for patients with newly diagnosed intermediate- to high-risk diffuse large B-cell lymphoma. (formularywatch.com)
  • Laurie Sehn, MD, of the BC Cancer Agency, on abstract 629, "Brentuximab Vedotin Monotherapy in Diffuse Large B-Cell Lymphoma Patients With Undetectable CD30: Preliminary Results From a Phase II Study. (ascopost.com)
  • Laurie Sehn, MD, of the BC Cancer Agency, on abstract 393, "R-CHOP With or Without Radiotherapy in Nonbulky Limited-Stage Diffuse Large B-Cell Lymphoma: Preliminary Results of the Prospective Randomiz. (ascopost.com)
  • Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 393, "R-CHOP With or Without Radiotherapy in Nonbulky Limited-Stage Diffuse Large B-Cell Lymphoma: Prelimina. (ascopost.com)
  • More recently, promising results for duvelisib for patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) suggest that this could also be an indication for the drug in the future. (medscape.com)
  • Nodal peripheral T-cell lymphoma with T-follicular helper phenotype (NPTCL-TFH) is a subset of peripheral T-cell lymphoma defined by expression of at least 2 or 3 TFH markers. (researchsquare.com)
  • As for a new umbrella category of PTCL, nodal peripheral T-cell lymphoma with T-follicular helper phenotype (NPTCL-TFH) was firstly classified in the 2017 revision of the World Health Organization (WHO) classification of hematolymphoid neoplasms. (researchsquare.com)
  • We report here a case of NPTCL-TFH with aberrant CD20 expression, hoping to provide cases and more cognition on this new type of peripheral T-cell lymphoma. (researchsquare.com)
  • Small lymphocytic lymphoma is a low-grade lymphoma, is composed of mature lymphocytes (nearly always B cells), and occurs in the elderly. (wisc.edu)
  • Lymphomas are cancers of lymphocytes. (webmd.com)
  • In lymphoma, white blood cells called B lymphocytes or T lymphocytes grow out of control because of a mutation. (healthline.com)
  • The procedure is similar to donating blood, but instead of going into a collecting bag, the blood goes into a special machine that separates out the lymphocytes (including lymphoma cells). (cancer.org)
  • Some skin lymphomas start in B-lymphocytes. (bccancer.bc.ca)
  • The most important of these discoveries has been the demonstration of curability of lymphoma which has re-invigorated efforts to use chemotherapy to treat cancer and helped establish some of the key principles of chemotherapy, affecting cancers more broadly, including combined modality therapy, attention to tumor lysis syndrome, and treatment of sanctuary sites. (biomedcentral.com)
  • He would be doing a 16 week Chemotherapy program that would hopefully put the Lymphoma into remission and allow him to continue living the happiest life he can live. (gofundme.com)
  • Jane Fonda, seen here in 2018, has announced she is undergoing chemotherapy to treat non-Hodgkin's Lymphoma. (cnn.com)
  • Jane Fonda has been diagnosed with non-Hodgkin's Lymphoma and has begun chemotherapy treatment, the legendary actress and activist said in post shared on her verified social media account. (cnn.com)
  • R-CHOP is the acronym for the combination of drugs that are commonly used as chemotherapy for certain cancers, such as non-Hodgkin lymphomas (NHLs). (verywellhealth.com)
  • The prognosis for patients with thyroid large-cell lymphoma usually is favorable because they typically present with localized disease, which is amenable to treatment with chemotherapy and radiation (see Treatment ). (medscape.com)
  • Was diagnosed with Anaplastice Large cell Lymphoma in 2005 - - chemotherapy and radiation. (volunteermatch.org)
  • If the lymphoma comes back after successful treatment (relapse) or if the lymphoma does not respond to conventional treatments (refractory), higher dose chemotherapy with or without radiation followed by a stem cell transplant (rescue) may offer the best chance of cure. (childrensoncologygroup.org)
  • To determine the efficacy and toxicity of chemoimmunotherapy followed by either whole-brain radiotherapy (WBRT) or intensive chemotherapy and autologous stem-cell transplantation (ASCT) as a first-line treatment of primary CNS lymphoma (PCNSL). (nih.gov)
  • Revised response criteria for malignant lymphoma. (medscape.com)
  • The incidence of lymphoproliferative ocular diseases, especially malignant lymphoma, has increased over the years. (medscape.com)
  • Farming and malignant lymphoma in Hancock County, Ohio. (cdc.gov)
  • The clinical data of one patient who was misdiagnosed as chronic tonsillitis and finally diagnosed as malignant lymphoma of tonsil were analyzed retrospectively. (scitechnol.com)
  • To summarize and reflect on the clinical manifestations, diagnosis and treatment of malignant lymphoma of tonsil, so as to improve the clinical understanding and diagnosis of this disease. (scitechnol.com)
  • Lymphoma external icon is a general term for cancers that start in the lymph system (the tissues and organs that produce, store, and carry white blood cells that fight infections). (cdc.gov)
  • Lymphomas are cancers of the lymph system, a part of your immune system that helps fight off infections. (healthline.com)
  • Non-Hodgkin lymphomas (NHL) are a group of blood cancers that vary significantly in their severity, from slow growing to very aggressive. (patientslikeme.com)
  • Analyzing circulating tumor DNA (ctDNA) in patients with lymphomas and other cancers -- the experimental technique often called "liquid biopsy" -- may eventually become a valuable prognostic and diagnostic tool, providing better and faster information than imaging, but the data need to accumulate. (medpagetoday.com)
  • 2. The most common cancers in the African Region are cancers of the cervix, breast, liver and prostate as well as Kaposi's sarcoma and non-Hodgkin's lymphoma. (who.int)
  • This research will test the combination of two new drugs, called ibrutinib and ABT199, taken together in the treatment of Mantle Cell Lymphoma. (clinicaltrials.gov)
  • Other studies have indicated the potential for these drugs to be used in the treatment of participants with Mantle Cell Lymphoma. (clinicaltrials.gov)
  • In this study, the investigators will test the combination of the two drugs together, in order to determine what effects (good and bad) it has on mantle cell lymphoma. (clinicaltrials.gov)
  • Therefore the effectiveness of the combination of the study drugs will be assessed, as will how they affect mantle cell lymphoma and how it develops resistance to the treatments. (clinicaltrials.gov)
  • ATLANTA, Georgia - Lenalidomide ( Revlimid ), an immunomodulatory agent approved for use in multiple myeloma, has shown promise in the treatment of mantle cell lymphoma (MCL), one of the rarest non-Hodgkin's lymphomas. (medscape.com)
  • There is only one drug approved so far for mantle cell lymphoma - bortezomib ( Velcade ). (medscape.com)
  • Phase 2 trials have shown activity across the board in lymphomas with lenalidomide, but especially in mantle cell lymphoma," explained Dr. Goy. (medscape.com)
  • Cite this: Lenalidomide Holds Promise in Mantle Cell Lymphoma - Medscape - Dec 20, 2012. (medscape.com)
  • Mantle cell lymphoma is an aggressive lymphoma of small B-cells derived from the follicle mantle. (wisc.edu)
  • Mantle cell lymphoma (MCL) is a relatively rare cancer of the lymphoid cells that arise from the outer rim or mantle lymphoid follicle. (rxlist.com)
  • What causes mantle cell lymphoma? (rxlist.com)
  • What are risk factors for mantle cell lymphoma? (rxlist.com)
  • What are signs and symptoms of mantle cell lymphoma? (rxlist.com)
  • What types of health care professionals diagnose and treat mantle cell lymphoma? (rxlist.com)
  • What tests do health care professionals use to diagnose mantle cell lymphoma? (rxlist.com)
  • [ 9 ] Separate indices have been developed for follicular and mantle cell lymphoma. (medscape.com)
  • Laurie Sehn, MD, of the BC Cancer Agency, on abstract 625, "Sustained Remission With the Combination Biologic Doublet of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma: A Mu. (ascopost.com)
  • Over the years, different systems have been used to classify lymphomas, including the Rappaport Classification (used until the 1970s), the Working Formulation, the National Cancer Institute Working Formulation, and the Revised European-American Lymphoma Classification (REAL). (medscape.com)
  • In a very large phase 2 trial, lenalidomide showed "rapid and durable efficacy" in the treatment of MCL, and the safety profile "is what you'd expect," said lead author Andre Goy, MD, MS, chair, director, and chief of lymphoma at the John Theurer Cancer Center in Hackensack, New Jersey. (medscape.com)
  • A lymphoma is a type of cancer arising from lymphoid cells . (wikipedia.org)
  • Myc oncogenetic deregulation is abundantly described in several solid human cancer and lymphomas. (biomedcentral.com)
  • The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against cancer. (lls.org)
  • Lymphoplasmacytic lymphoma (LPL) is a rare type of slowly developing cancer that mostly affects older adults. (healthline.com)
  • Dr. Morando Soffritti found aspartame to be a multipotential carcinogen causing everything from leukemia and lymphoma to lung, liver and breast cancer. (rense.com)
  • The Lymphoma Research Foundation's mission is to eradicate lymphoma and serve those impacted by this blood cancer. (lymphoma.org)
  • At McGill University, researcher Sayeh Davoudi at the Goodman Cancer Research Center will study the role of polymerase in the generation of point mutations, and Gabriela Galicia Vazquez will study a eukaryotic initiation factor as a molecular target for lymphoma treatment. (genomeweb.com)
  • Non-Hodgkin's Lymphoma is a cancer of the immune system. (cnn.com)
  • It may be used alone, or it may be used along with other drugs or treatments, or to treat other types of cancer besides lymphoma. (verywellhealth.com)
  • A cohort study of 2215 patients with primary thyroid lymphoma from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute reported 5- and 10-year overall survival rates of 71.61% and 55.95%, respectively. (medscape.com)
  • CT , blood tests, and immunotyping (examining the specific molecules expressed on the surface of the lymphoma cells) of cancer cells may be done to further delineate the spread and other characteristics of your MCL. (rxlist.com)
  • Mayo Clinic Comprehensive Cancer Center is one of a handful of facilities that received a U.S. National Cancer Institute Specialized Program of Research Excellence (SPORE) grant for lymphoma research . (mayoclinic.org)
  • According to the Mayo Clinic , "lymphoma is a cancer of the lymphatic system, which is part of the body's germ-fighting network. (katc.com)
  • COG is a member of the National Cancer Institute's National Clinical Trials Network (NCTN) and the Theraputic Advances in Childhood Leukemia & Lymphoma Consortium (TACL). (ohsu.edu)
  • In 2014, the International Conference on Malignant Lymphomas (a multidisciplinary team of researchers representing major lymphoma clinical trial groups and cancer centers from North America, Europe, Japan, and Australasia) published guidelines for the evaluation, staging, and response assessment of patients with malignant lymphomas. (medscape.com)
  • Cutaneous T-cell lymphomas are rare types of cancer. (aacr.org)
  • Amongst cancer types, lymphoma has had a recent surge in excitement and development of liquid biopsy tests for diagnosis of relapse and/or prediction of outcomes. (medpagetoday.com)
  • The case-control studies provide some support for associations between Perc exposure and cancer of the breast, bladder, and lymphoma although most of the increases were not statistically sufficient. (who.int)
  • Anaplastic large-cell lymphoma is a rare tumor occurring in children and adults groups. (wisc.edu)
  • The clinical course is similar to that of large cell lymphoma. (wisc.edu)
  • primary thyroid lymphoma may constitute 1-8% of all thyroid malignancies and 1-7% of all extranodal lymphomas. (medscape.com)
  • This type of lymphoma represents 1% of NHLs, 1% of intracranial tumors, and less than 1% of intraocular tumors. (medscape.com)
  • Primary thyroid lymphomas are practically always non-Hodgkin lymphomas (NHLs). (medscape.com)
  • It accounts for 40 and 50% of childhood non-Hodgkin's lymphomas (NHLs) and 1-2% of adult lymphomas in Western Europe and the United States Footnote 8 . (canada.ca)
  • The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. (lls.org)
  • That was one of 959 comments, but ironically commenting just above was David Mutnick, one of Team In Training's Pop's Warrior team, a group of some 13 Team In Training teammates travelling to Disney for the third time to support The Leukemia & Lymphoma Society (LLS). (teamintraining.org)
  • Over three years the team has raised more than $200,000 for The Leukemia & Lymphoma Society. (teamintraining.org)
  • What is your connection to The Leukemia & Lymphoma Society of Canada? (llscanada.org)
  • If you donate and have not already registered, you will receive periodic updates and communications from The Leukemia & Lymphoma Society of Canada. (llscanada.org)
  • Survival rates for children diagnosed with Burkitt lymphoma (BL) in Africa are far below those achieved in developed countries. (biomedcentral.com)
  • First described in 1958 in Uganda, Burkitt lymphoma (BL) attracted interest worldwide following reports of its uneven geographic distribution and rapidly fatal clinical course. (biomedcentral.com)
  • Epstein Barr virus (EBV) is a gammaherpesvirus that is associated with nasopharyngeal carcinoma (NPC) and endemic Burkitt lymphoma (eBL). (biomedcentral.com)
  • Burkitt lymphoma and Burkitt leukemia are different forms of the same disease. (oncolink.org)
  • C83.78 is a billable ICD code used to specify a diagnosis of burkitt lymphoma, lymph nodes of multiple sites. (icd.codes)
  • Thomas RK, Re D, Wolf J, Diehl V. Part I: Hodgkin's lymphoma--molecular biology of Hodgkin and Reed-Sternberg cells. (medscape.com)
  • Re D, Kuppers R, Diehl V. Molecular pathogenesis of Hodgkin's lymphoma. (medscape.com)
  • Characteristics of Hodgkin's lymphoma after infectious mononucleosis. (medscape.com)
  • Lenalidomide has demonstrated tumoricidal and antiproliferative effects in MCL and clinical activity and safety in multiple phase 2 studies in aggressive non-Hodgkin's lymphoma. (medscape.com)
  • Martí-Carvajal AJ, Cardona AF, Lawrence A. Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma. (medscape.com)
  • Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. (medscape.com)
  • of non-Hodgkin's lymphoma , primary cerebral lymphoma and Hodgkin's disease are all increased. (wikipedia.org)
  • Non-Hodgkin's lymphoma (NHL) is present in about 1%-3% of HIV seropositive people at the time of the initial diagnosis of HIV. (wikipedia.org)
  • There are many categories of non-Hodgkin's lymphoma and the main types will be briefly described. (wisc.edu)
  • In late September of 2002, Melissa Leigh Sutton, age 24, was diagnosed with Hodgkin's Lymphoma. (angelfire.com)
  • Only about 7,000 cases of Hodgkin's Lymphoma occur in the United States each year. (angelfire.com)
  • This was when we found out that the diagnosis was definitely Hodgkin's Lymphoma. (angelfire.com)
  • Her diagnosis was Hodgkin's Lymphoma nodular sclerosis Stage I B, bulky disease. (angelfire.com)
  • Lymphoplasmacytic lymphoma (LPL) is a type of non-Hodgkin's lymphoma that commonly causes anemia or swollen lymph nodes. (healthline.com)
  • Hodgkin's lymphoma is caused by abnormally-growing cells in the lymphatic system that may spread elsewhere in the body. (bmc.org)
  • MCL is an aggressive B-cell type of non-Hodgkin's lymphoma. (rxlist.com)
  • MCL is an aggressive B-cell type of non-Hodgkin's lymphoma , and the rare disease accounts for about 2%-10% of non-Hodgkin's lymphomas . (rxlist.com)
  • Mayo Clinic is an international leader in non-Hodgkin's lymphoma research. (mayoclinic.org)
  • A case control study, based on death certificates, was conducted of non Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) among white males in Hancock County, Ohio. (cdc.gov)
  • When you share what it's like to have non-Hodgkin's lymphoma through your profile, those stories and data appear here too. (patientslikeme.com)
  • Got a question about living with non-Hodgkin's lymphoma? (patientslikeme.com)
  • Who has non-Hodgkin's lymphoma on PatientsLikeMe? (patientslikeme.com)
  • Optic neuropathy secondary to lymphomatous infiltration of the optic nerve developed in a patient who was in complete remission from treatment of a non-Hodgkin's lymphoma. (wisc.edu)
  • This is the first reported case of an isolated optic neuropathy occurring in a patient in clinical and laboratory remission of non-Hodgkin's lymphoma. (wisc.edu)
  • We report a 51-yr male who presented with fever, fatigue and syncopal episodes and with past medical history of non-Hodgkin's lymphoma in remission for 3 years, and hepatitis C. He developed severe lactic acidosis and eventually succumbed despite adequate and timely interventions. (openurologyandnephrologyjournal.com)
  • The clinical presentation resulting from the recurrence of non-Hodgkin's lymphoma was evident from the initial dramatic response to steroid therapy and confirmed subsequently on histopathology. (openurologyandnephrologyjournal.com)
  • It is a high-grade B-cell non-Hodgkin's lymphoma with endemic, sporadic and human immunodeficiency-associated subtypes. (bvsalud.org)
  • Other malignant diseases in immunocompetent hosts include various B-cell or T-cell lymphomas, and epithelial or mesenchymal carcinomas such as classical Hodgkin's lymphoma and nasopharyngeal carcinoma Footnote 6 Footnote 7 Footnote 10 . (canada.ca)
  • This guideline covers diagnosing and managing non-Hodgkin's lymphoma in people aged 16 years and over. (bvsalud.org)
  • It aims to improve care for people with non-Hodgkin's lymphoma by promoting the best tests for diagnosis and staging and the most effective treatments for 6 of the subtypes. (bvsalud.org)
  • A 2021 in-vitro study stated that it is also associated with over 80% of angioimmunoblastic T-cell lymphoma (AITL). (medicalnewstoday.com)
  • On June 30, 2021, the Food and Drug Administration approved asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze, Jazz Pharmaceuticals, Inc.) as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase. (fda.gov)
  • The prognosis for ocular lymphoma depends on the tumor's histologic type and stage and the treatment employed. (medscape.com)
  • it was approved in 2018 for the same two indications and also for use in the treatment of small lymphocytic lymphoma (CLL/SLL). (medscape.com)
  • At the time of its US approval, Ian Flinn, MD, PhD, director of the Lymphoma Research Program at Sarah Cannon Research Institute, Nashville, Tennessee, said, "Duvelisib is an important addition to the evolving treatment paradigm for patients with CLL/SLL and FL. (medscape.com)
  • Treatment of AIDS patients with antiretroviral drugs reduces the incidence of primary cerebral lymphoma. (wikipedia.org)
  • It can also be used to get a second opinion with another specialist to confirm the patient's diagnosis and evaluate if the course of treatment is the most appropriate based on the type of lymphoma. (lymphoma.org)
  • We use imaging tests to see whether lymphoma has spread or how well treatment is working. (ohsu.edu)
  • In the initial period after active treatment, the doctor who was taking care of you during your lymphoma experience will probably want to see you regularly, usually every few months for the first year or two and less often after that. (lymphoma.ca)
  • However, despite recent advances in treatment of lymphoma, our methods for assessing the disease have remained largely unchanged in several decades -- current methods include biopsies, computed tomography (CT) scans, and positron emission tomography (PET) scans, but these all have limitations. (medpagetoday.com)
  • This work verified the social representations about health of individuals with leukemia and lymphoma, and social practices adopted upon treatment. (bvsalud.org)
  • The LFC seeks to provide: funding for research fellowships in Canada in connection with the prevention, treatment and cure of lymphoma. (bvsalud.org)
  • Near the time of her admission, the disease progressed, and venetoclax, a B-cell lymphoma 2 inhibitor, was added to her treatment. (cdc.gov)
  • Skin lymphomas are also called T-cell lymphomas (CTCL), mycosis fungoides and Sezary syndrome. (bccancer.bc.ca)
  • Similar to mycosis fungoides but the lymphoma cells are also in the blood or lymph nodes. (bccancer.bc.ca)
  • The FDA has approved a new immunotherapeutic for treating two types of cutaneous T-cell lymphoma, mycosis fungoides and Sézary syndrome. (aacr.org)
  • Mycosis fungoides and Sézary syndrome account for about two-thirds of cutaneous T-cell lymphomas. (aacr.org)
  • What Factors Affect the Prognosis for Stage 4 Lymphoma? (reference.com)
  • Factors that affect the prognosis for stage IV lymphoma include the specific type diagnosed, daily living routine, age, the level of lactate dehydrogenase in the blood, and the extent of the disease, says Healthline. (reference.com)
  • The prognosis for slow-growing lymphomas considers hemoglobin levels in the blood. (reference.com)
  • Hence, all patients with ocular lymphoma should have a complete workup to rule out systemic lymphoma. (medscape.com)
  • The diagnostic workup of lymphoma continues to evolve rapidly as experience and discovery lead to the addition of new clinicopathologic entities and techniques to differentiate them. (medscape.com)
  • The American Society for Clinical Pathology, the College of American Pathologists, and the American Society of Hematology convened a panel of experts in the laboratory workup of lymphoma to develop evidence-based recommendations. (medscape.com)
  • To address the uncertainty related to the workup of suspected lymphomas, the American Society for Clinical Pathology (ASCP), the College of American Pathologists (CAP), and the American Society of Hematology (ASH) convened a joint workgroup to develop an evidence-based guideline to address appropriate evaluative processes. (medscape.com)
  • The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. (lls.org)
  • PMR has presented a comprehensive report based on Bone Marrow Transplantation market as per End User (Hospitals, Multispecialty Clinics, and Ambulatory Surgical Centers), Disease Indication (Leukemia, Lymphoma, Myeloma, and Others), Transplant Type (Autologous Bone Marrow Transplant, and Allogeneic Bone Marrow Transplant) based on seven regions. (openpr.com)
  • Marginal zone B-cell lymphoma is composed of small cells and monocytoid cells (with more abundant cytoplasm) and is a low-grade lymphoma. (wisc.edu)
  • Primary cutaneous marginal zone B-cell lymphomas. (bccancer.bc.ca)
  • Retrieved from https://www.hematology.org/education/clinicians/drug-resources/fda-alerts/2019/fda-approves-lenalidomide-follicular-marginal-zone-lymphoma . (hematology.org)
  • Yet, even as the diagnostic process for lymphoma has grown more complex and requires application of an ever-growing array of ancillary diagnostic techniques, clinical practice has shifted progressively toward less invasive procedures. (medscape.com)
  • The clinical literature regards CT as the standard of care for the imaging-based staging of lymphoma. (diagnosticimaging.com)
  • Primary cutaneous B-cell lymphoma is an uncommon neoplasm with classification schemes that may be confusing, but with clinical presentations that are relatively consistent. (elsevier.com)
  • The incidence of ocular lymphoma increases with advancing age. (medscape.com)
  • Caractéristiques épidémiologiques et évolution de l'incidence des lymphomes cérébraux primitifs observés chez 80 patients infectés par le VIH entre 1983 et 1999" [Epidemiological features and incidence trends of primary cerebral lymphomas observed in 80 HIV-infected patients from 1983 to 1999]. (wikipedia.org)
  • In contrast, EBV-associated sporadic lymphoma occurs in children and young adults and has no specific geographic distribution, with an incidence of 2-3 cases per 1,000,000 individuals Footnote 7 . (canada.ca)
  • It may be either a primary intraocular lymphoma (PIOL) or a secondary intraocular lymphoma (SIOL). (medscape.com)
  • PIOL is mainly a subtype of primary CNS lymphoma (PCNSL). (medscape.com)
  • Primary CNS lymphoma in children and adolescents: a descriptive analysis from the international primary CNS lymphoma collaborative group (IPCG). (medscape.com)
  • Primary cerebral lymphoma (or primary central nervous system lymphoma ) is a form of NHL. (wikipedia.org)
  • Primary cerebral lymphoma is strongly associated with Epstein-Barr virus (EBV). (wikipedia.org)
  • [6] The presence of EBV DNA in cerebrospinal fluid is highly suggestive of primary cerebral lymphoma. (wikipedia.org)
  • Primary diagnosis and classification of lymphoma can be achieved with a variety of specimens. (medscape.com)
  • Although accurate prediction of outcome has long been a primary goal of lymphoma classification, direction of management was a secondary goal in some respects-historically, because of limited available therapeutic options. (medscape.com)
  • Primary thyroid lymphoma can be defined as a lymphoma that arises from the thyroid gland. (medscape.com)
  • patients with Hashimoto thyroiditis have a 60 times higher risk of developing primary thyroid lymphoma, compared with the general population. (medscape.com)
  • Primary thyroid lymphoma is rare. (medscape.com)
  • Primary cutaneous follicle centre lymphoma. (bccancer.bc.ca)
  • Primary cutaneous B-cell lymphoma in a 74-year-old Caucasian male. (elsevier.com)
  • Peripheral T-cell lymphomas (PTCLs) are rare, aggressive lymphomas that affect mature T cells. (medicalnewstoday.com)
  • If a doctor suspects a person has lymphoma, they will request a lymph node biopsy, where a healthcare professional removes part or the entire lymph node for lab analysis. (medicalnewstoday.com)
  • They are most useful for more advanced or quickly growing skin lymphomas. (cancer.org)
  • It is sometimes used for T-cell skin lymphomas, especially Sezary syndrome . (cancer.org)
  • Skin lymphomas behave very differently from other lymphomas. (bccancer.bc.ca)
  • What are the types of skin lymphomas? (bccancer.bc.ca)
  • There are many types of skin lymphomas. (bccancer.bc.ca)
  • Most skin lymphomas are T-cell lymphomas, sometimes called cutaneous T-cell lymphomas (CTCLs). (bccancer.bc.ca)
  • About half of all skin lymphomas. (bccancer.bc.ca)
  • Peripheral T-cell lymphomas occur more frequently in adults and are much less common than B cell lymphomas in the United States. (wisc.edu)
  • LPL can resemble other B-cell lymphomas with similar types of plasma cell differentiation. (healthline.com)
  • These are called cutaneous B-cell lymphomas. (bccancer.bc.ca)
  • Non-Hodgkin lymphomas with these disease characteristics are grouped together and called cutaneous cutaneous T-cell lymphomas . (aacr.org)
  • In AIDS patients or other immunosuppressed patients, many EBV-associated diseases may occur, such as oral hairy leukoplasia, interstitial lymphocytic pneumonia, B-cell or T-cell lymphomas and mesenchymal lymphomas (for e.g. leiomyosarcoma) Footnote 1 Footnote 2 Footnote 3 Footnote 4 Footnote 7 . (canada.ca)
  • Whole-body MRI with a nonenhanced imaging sequence can provide accurate staging of lymphoma. (diagnosticimaging.com)
  • Whole-body MR with short-tau inversion recovery (STIR) imaging has been shown to be a credible noninvasive alternative for lymphoma staging. (diagnosticimaging.com)
  • Principal investigator Dr. Darren D. Brennan, a radiologist at the Mater Misericordiae Hospital, and colleagues enrolled 23 consecutive lymphoma patients in their study and compared multislice CT and MR scanning for staging of disease. (diagnosticimaging.com)
  • The symptoms of AIDS-related lymphoma can include: weight loss, fever, and night sweats. (wikipedia.org)
  • The surgeons said that from her symptoms, it appeared that she was suffering from some type of lymphoma. (angelfire.com)
  • People with skin lymphoma may have symptoms for years before being diagnosed. (bccancer.bc.ca)
  • Lymphomas are malignant neoplasms of lymphoid cells and are divided into Hodgkin's disease and non-Hodgkin's lymphomas. (wisc.edu)
  • Hodgkin's disease of lymphoma is divided into classic forms characterized by presence of classic Reed-Sternberg cells, and lymphocyte predominant type characterized by absence of classic Reed Sternberg cell and presence of atypical B cells with polylobated nuclei. (wisc.edu)
  • This has changed dramatically in recent years given the proliferation of disease-specific regimens and the explosion of novel agents that show targeted activity in distinct subtypes of lymphoma. (medscape.com)
  • Systemic chemo is not often used for early skin lymphoma, but it may be used if the disease in the skin is more advanced and no longer getting better with other treatments. (cancer.org)
  • Definition of "bulky" disease varies, depending on lymphoma histology. (medscape.com)
  • this represents the first worldwide consensus document on lymphoma classification. (medscape.com)
  • The diagnosis and classification of lymphoma has evolved into a complex, multimodality process that requires rigorous attention to and quality assurance of numerous preanalytical, analytical, and postanalytical details. (medscape.com)
  • Lymphoblastic lymphoma is a high-grade lymphoma, is composed of precursor T or B lymphoid cells, and can occur in all age groups but is more common in the young. (wisc.edu)
  • For example, an infection with the human T-cell lymphotropic virus type 1 (HTLV-1) can cause adult T-cell lymphoma/leukemia (ATLL). (medicalnewstoday.com)
  • Mayo applies that research to developing more effective and less toxic treatments for all forms of lymphoma. (mayoclinic.org)